<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">vhsNMkdHvZzQTZ7qgMZmZLN</article-id>
      <article-id pub-id-type="other">00015</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000800015</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300215</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000800015</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Qualidade de vida e indicadores cl&#237;nicos na insufici&#234;ncia card&#237;aca: an&#225;lise multivariada</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>Jefferson Jovelino Amaral dos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Plewka</surname>
            <given-names>Jony Erwin Andreola</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brofman</surname>
            <given-names>Paulo Roberto Slud</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Toledo</named-content>
          <named-content content-type="state">Paran&#225;</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Paranaense</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Curitiba</named-content>
          <named-content content-type="state">Paran&#225;</named-content>
        </addr-line>
        <institution content-type="orgname">Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;</institution>
        <institution content-type="orgdiv1">Programa de Doutorado em Ci&#234;ncias da Sa&#250;de </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Toledo</named-content>
          <named-content content-type="state">PR</named-content>
        </addr-line>
        <institution content-type="orgname">Instituto de Cardiologia de Toledo</institution>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>08</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>2</issue>
      <fpage>159</fpage>
      <lpage>166</lpage>
      <history>
        <date date-type="accepted">
          <day>24</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>06</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>16</day>
          <month>03</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: Na Insufici&#234;ncia Card&#237;aca (IC), a aten&#231;&#227;o especial &#233; necess&#225;ria n&#227;o somente em rela&#231;&#227;o &#224; aspectos objetivos ou isolados, mas tamb&#233;m &#224;s percep&#231;&#245;es de sa&#250;de do paciente. Os aspectos subjetivos podem ajudar os profissionais da sa&#250;de a entender e a melhor tratar a IC. OBJETIVO: O objetivo desse estudo foi avaliar simultaneamente os efeitos dos indicadores cl&#237;nicos da IC na qualidade de vida (QDV). M&#201;TODOS: Investigamos, atrav&#233;s de an&#225;lise multivariada, a QDV de 101 pacientes ambulatoriais brasileiros, utilizando o question&#225;rio de Minnesota (Minnesota Living with Heart Failure Questionnaire), incluindo suas sub-escalas, e sua correla&#231;&#227;o com as vari&#225;veis cl&#237;nicas e psicol&#243;gicas, tais como idade, etnia, g&#234;nero, par&#226;metros ecocardiogr&#225;ficos, &#237;ndice de massa corporal, press&#227;o arterial m&#233;dia de repouso, tempo de diagn&#243;stico, Classifica&#231;&#227;o Funcional de acordo com a NYHA, capacidade funcional atrav&#233;s de uma Escala de Atividade Espec&#237;fica, comorbidades, Escore de Risco de Framingham (ERF), teste de fun&#231;&#227;o pulmonar (espirometria) e composi&#231;&#227;o corporal. RESULTADOS: A QDV mostrou correla&#231;&#245;es univariadas significantes com o ecocardiograma: fra&#231;&#227;o de eje&#231;&#227;o (p=0,0415), di&#226;metro diast&#243;lico do ventr&#237;culo esquerdo (DDVE) (p=0,004), di&#226;metro sist&#243;lico do ventr&#237;culo esquerdo (DSVE) (p=0,0001); comorbidades (p=0,002) e teste de fun&#231;&#227;o pulmonar: Capacidade Vital For&#231;ada (CVF) (p&lt;0,0001), Volume Expirat&#243;rio For&#231;ado no 1&#186; segundo (FEV1) (p&lt;0,0001) e Ventila&#231;&#227;o Volunt&#225;ria M&#225;xima (VVM) (p=0,001). Na an&#225;lise multivariada, o protocolo Backward Stepwise detectou importantes vari&#225;veis influentes simult&#226;neas (r&#178;=0.60): g&#234;nero (0,000178), etnia (p&lt;0,00001), DSVE (p&lt;0,00001), ERF (p=0,000002), CVF (p=0,002027), FEV1 (p&lt;0,00001) e VVM (p=0,00001). CONCLUS&#195;O: G&#234;nero, etnia, DSVE, ERF, CVF, FEV1 e VVM s&#227;o preditores independentes de QDV em pacientes com IC. Simultaneamente, eles s&#227;o respons&#225;veis por cerca de 60% da vari&#226;ncia da QDV. Os aspectos biopsicossociais podem contribuir para as expectativas dos pacientes e profissionais de sa&#250;de e resultado do tratamento.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>qualidade de vida</kwd>
        <kwd>sa&#250;de hol&#237;stica</kwd>
        <kwd>an&#225;lise multivariada</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>13</day>
        <month>10</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGOS ORIGINAIS </p>
    <p> INSUFICI&#202;NCIA CARD&#205;ACA</p>
    <p>
      <bold>Qualidade de vida e indicadores cl&#237;nicos na insufici&#234;ncia card&#237;aca: an&#225;lise multivariada</bold>
    </p>
    <p>
      <bold>Jefferson Jovelino Amaral dos Santos<sup>I</sup>; Jony Erwin Andreola Plewka<sup>II</sup>; Paulo Roberto Slud Brofman<sup>III</sup></bold>
    </p>
    <p><sup>I</sup>Universidade Paranaense (UNIPAR), Toledo, PR </p>
    <p><sup>II</sup>Instituto de Cardiologia de Toledo, Toledo, PR </p>
    <p><sup>III</sup>Programa de Doutorado em Ci&#234;ncias da Sa&#250;de (PUCPR), Curitiba, PR, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="not1">Correspond&#234;ncia</xref>
      <a href="#cor" link-type="internal"/>
      <a href="#cor" link-type="internal"/>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> Na Insufici&#234;ncia Card&#237;aca (IC), a aten&#231;&#227;o especial &#233; necess&#225;ria n&#227;o somente em rela&#231;&#227;o &#224; aspectos objetivos ou isolados, mas tamb&#233;m &#224;s percep&#231;&#245;es de sa&#250;de do paciente. Os aspectos subjetivos podem ajudar os profissionais da sa&#250;de a entender e a melhor tratar a IC. </p>
    <p><bold>OBJETIVO:</bold> O objetivo desse estudo foi avaliar simultaneamente os efeitos dos indicadores cl&#237;nicos da IC na qualidade de vida (QDV). </p>
    <p><bold>M&#201;TODOS:</bold> Investigamos, atrav&#233;s de an&#225;lise multivariada, a QDV de 101 pacientes ambulatoriais brasileiros, utilizando o question&#225;rio de Minnesota (Minnesota Living with Heart Failure Questionnaire), incluindo suas sub-escalas, e sua correla&#231;&#227;o com as vari&#225;veis cl&#237;nicas e psicol&#243;gicas, tais como idade, etnia, g&#234;nero, par&#226;metros ecocardiogr&#225;ficos, &#237;ndice de massa corporal, press&#227;o arterial m&#233;dia de repouso, tempo de diagn&#243;stico, Classifica&#231;&#227;o Funcional de acordo com a NYHA, capacidade funcional atrav&#233;s de uma Escala de Atividade Espec&#237;fica, comorbidades, Escore de Risco de Framingham (ERF), teste de fun&#231;&#227;o pulmonar (espirometria) e composi&#231;&#227;o corporal. </p>
    <p><bold>RESULTADOS:</bold> A QDV mostrou correla&#231;&#245;es univariadas significantes com o ecocardiograma: fra&#231;&#227;o de eje&#231;&#227;o (p=0,0415), di&#226;metro diast&#243;lico do ventr&#237;culo esquerdo (DDVE) (p=0,004), di&#226;metro sist&#243;lico do ventr&#237;culo esquerdo (DSVE) (p=0,0001); comorbidades (p=0,002) e teste de fun&#231;&#227;o pulmonar: Capacidade Vital For&#231;ada (CVF) (p&lt;0,0001), Volume Expirat&#243;rio For&#231;ado no 1&#186; segundo (FEV<sub>1</sub>) (p&lt;0,0001) e Ventila&#231;&#227;o Volunt&#225;ria M&#225;xima (VVM) (p=0,001). Na an&#225;lise multivariada, o protocolo Backward Stepwise detectou importantes vari&#225;veis influentes simult&#226;neas (r<sup>2</sup>=0.60): g&#234;nero (0,000178), etnia (p&lt;0,00001), DSVE (p&lt;0,00001), ERF (p=0,000002), CVF (p=0,002027), FEV<sub>1</sub> (p&lt;0,00001) e VVM (p=0,00001). </p>
    <p><bold>CONCLUS&#195;O:</bold> G&#234;nero, etnia, DSVE, ERF, CVF, FEV<sub>1</sub> e VVM s&#227;o preditores independentes de QDV em pacientes com IC. Simultaneamente, eles s&#227;o respons&#225;veis por cerca de 60% da vari&#226;ncia da QDV. Os aspectos biopsicossociais podem contribuir para as expectativas dos pacientes e profissionais de sa&#250;de e resultado do tratamento.</p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca, qualidade de vida, sa&#250;de hol&#237;stica, an&#225;lise multivariada. </p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A avalia&#231;&#227;o da qualidade de vida (QDV) tem se tornado indispens&#225;vel ao avaliar-se um paciente na pr&#225;tica cl&#237;nica. A Organiza&#231;&#227;o Mundial da Sa&#250;de (OMS) define QDV como "a percep&#231;&#227;o do indiv&#237;duo em rela&#231;&#227;o &#224; sua posi&#231;&#227;o na vida de acordo com o contexto cultural e os sistemas de valores nos quais vive e em rela&#231;&#227;o a seus objetivos, expectativas, padr&#245;es e preocupa&#231;&#245;es"<sup>1</sup>. </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) &#233; uma s&#237;ndrome cl&#237;nica resultante de um dist&#250;rbio card&#237;aco funcional ou estrutural que prejudica a capacidade do ventr&#237;culo de encher-se com ou ejetar sangue suficiente de acordo com a demanda do corpo, ou permite faz&#234;-lo apenas com press&#245;es de enchimento aumentadas. Sua preval&#234;ncia &#233; estimada em aproximadamente 2,3% na popula&#231;&#227;o geral<sup>2</sup> e 0,4% a 2% na popula&#231;&#227;o europ&#233;ia<sup>3</sup>; cerca de 5 milh&#245;es de pessoas nos EUA t&#234;m IC e a condi&#231;&#227;o resulta em cerca de 300.000 mortes todo ano. No Brasil, o maior pa&#237;s da Am&#233;rica do Sul, a IC &#233; a terceira causa de todas as hospitaliza&#231;&#245;es<sup>4</sup>. A IC n&#227;o &#233; apenas uma doen&#231;a de popula&#231;&#227;o espec&#237;fica, mas tamb&#233;m uma epidemia mundial. Pacientes com IC t&#234;m suas vidas prejudicadas pela doen&#231;a, e mesmo o tratamento otimizado parece ter diferentes impactos em sua QDV. Seu manejo envolve uma equipe multiprofissional que precisa cuidar da condi&#231;&#227;o cl&#237;nica do paciente, h&#225;bitos nutricionais, controle do peso, cuidados n&#227;o-farmacol&#243;gicos (exerc&#237;cio, educa&#231;&#227;o, etc.)<sup>3</sup> Considerando esses pontos, a literatura mostra um espa&#231;o vazio significante entre o que os profissionais de sa&#250;de e os pacientes consideram objetivos importantes<sup>5</sup>, especialmente quando aspectos simult&#226;neos da doen&#231;a est&#227;o envolvidos. Assim, mais estudos s&#227;o necess&#225;rios para entender as rela&#231;&#245;es entre a patologia da IC e os sintomas e efeitos da IC na QDV dos pacientes<sup>6</sup>. Muitos esfor&#231;os t&#234;m sido feitos pela comunidade cient&#237;fica para relacionar aspectos subjetivos e objetivos da IC<sup>5,7</sup>. Essas considera&#231;&#245;es podem ajudar os profissionais da sa&#250;de a planejar estrat&#233;gias para tratar essa disfun&#231;&#227;o, n&#227;o apenas com foco nos fins objetivos, mas tamb&#233;m nas expectativas dos pacientes. </p>
    <p>O presente estudo foi desenvolvido para investigar a rela&#231;&#227;o dos aspectos mais comumente avaliados da IC e a QDV desses pacientes e como esses aspectos se comportam quando s&#227;o analisados na presen&#231;a de outros.</p>
    <p>
      <bold>Pacientes e m&#233;todos </bold>
    </p>
    <p>
      <bold>Popula&#231;&#227;o</bold>
    </p>
    <p>Um total de 137 pacientes ambulatoriais com IC (classe funcional I-III), usu&#225;rios do Sistema Publico de Sa&#250;de Brasileiro (SUS), foram recrutados; desses, 101 foram considerados na an&#225;lise final, pois retornaram os relat&#243;rios completamente preenchidos. </p>
    <p>Os crit&#233;rios de inclus&#227;o foram: os pacientes devem estar est&#225;veis, e ter um diagn&#243;stico cl&#237;nico de IC feito por especialista associado com FE <underline>&lt;</underline>45% na ecocardiografia (dentro de 2 meses), sem infarto do mioc&#225;rdio recente, bem como angina inst&#225;vel, acidente cerebrovascular, procedimento de revasculariza&#231;&#227;o coronariana por pelo menos 3 meses antes do in&#237;cio do estudo ou uso de marca-passo. Pacientes com caquexia ou dificuldades no desempenho de qualquer desses testes n&#227;o foram inclu&#237;dos no estudo.</p>
    <p>Os dados de caracteriza&#231;&#227;o baseados em relat&#243;rios cient&#237;ficos e pr&#225;tica cl&#237;nica, que levam em considera&#231;&#227;o o manejo da IC tais como g&#234;nero, etnia, &#237;ndice de massa corporal (IMC), press&#227;o arterial m&#233;dia de repouso (PAMR), tempo de diagn&#243;stico (TD) (h&#225; 2 anos ou mais de 2 anos), Classifica&#231;&#227;o Funcional de acordo da New York Heart Association (CF-NYHA), Escala de Atividade Espec&#237;fica (EAE) de Goldman<sup>8</sup> para medir a capacidade funcional, comorbidades relacionadas &#224; idade (&#205;ndice de Charlson)<sup>9</sup> e o escore de risco de Framingham (ER) de acordo com as diretrizes da Sociedade Brasileira de Cardiologia<sup>10,11</sup> foram avaliadas. </p>
    <p>
      <bold>Testes de fun&#231;&#227;o pulmonar</bold>
    </p>
    <p>Um teste espirom&#233;trico foi realizado de acordo com os padr&#245;es da Sociedade Tor&#225;cica Americana e Sociedade Respirat&#243;ria Europ&#233;ia<sup>12</sup> (Espir&#244;metro Pony Graphics, Cosmed, It&#225;lia). Dados como Capacidade Vital For&#231;ada (CVF), Volume Expirat&#243;rio For&#231;ado no primeiro segundo (FEV 1), raz&#227;o FEV 1/FVC% e Ventila&#231;&#227;o Volunt&#225;ria M&#225;xima (VVM) foram obtidos. Todos os valores foram expressos em porcentagens do total previsto para a popula&#231;&#227;o brasileira<sup>13</sup>.</p>
    <p>
      <bold>Composi&#231;&#227;o corporal </bold>
    </p>
    <p>A porcentagem de gordura corporal (Gordura%), Massa livre de gordura (MLG) e &#193;gua Corporal Total (ACT) foram medidos por imped&#226;ncia bioel&#233;trica (BF 907, Maltron International, Reino Unido). A resist&#234;ncia foi medida na posi&#231;&#227;o supina no lado direito como descrito por Lukaski e cols.<sup>14</sup>.</p>
    <p>
      <bold>Qualidade de vida</bold>
    </p>
    <p>A QDV foi medida com a vers&#227;o brasileira do question&#225;rio de Minnesota (Minnesota Living with Heart Failure Questionnaire), uma medida doen&#231;a-espec&#237;fica que avalia as percep&#231;&#245;es dos pacientes sobre a influ&#234;ncia da IC nos aspectos f&#237;sicos, socioecon&#244;micos e psicol&#243;gicos da vida<sup>15</sup>.Outra importante considera&#231;&#227;o sobre esse instrumento &#233; seu formato abrangente, f&#225;cil de aplicar e o fato de ter sido validado para a popula&#231;&#227;o brasileira<sup>16</sup>. Os participantes responderam os 21 itens usando uma escala de resposta de seis pontos (0-5). O resumo do escore total (escore global) pode variar de 0 a 105; um escore mais baixo reflete melhor QDV. Os escores nas 3 sub-escalas (dimens&#245;es) refletem dificuldades f&#237;sicas (quest&#245;es n<sup>o. </sup>2, 3, 4, 5, 6, 7, 12 e 13), emocionais (quest&#245;es n<sup>o. </sup>17, 18, 19, 20 e 21) e os outros itens est&#227;o relacionados &#224; considera&#231;&#245;es financeiras, efeitos colaterais de medicamentos e estilo de vida (dimens&#245;es gerais). Esse instrumento tamb&#233;m &#233; adequado para pacientes idosos<sup>17</sup>.</p>
    <p>Esse estudo foi aprovado pelo Comit&#234; de &#201;tica da Universidade Cat&#243;lica do Paran&#225; e todos os pacientes deram seu consentimento formal para sua participa&#231;&#227;o. </p>
    <p>
      <bold>An&#225;lise estat&#237;stica </bold>
    </p>
    <p>Estat&#237;stica descritiva foi computada para caracterizar a amostra atrav&#233;s de m&#233;dias &#177; desvios-padr&#227;o (<xref ref-type="table" rid="tab1">Tabela 1</xref>). A correla&#231;&#227;o bivariada foi feita para uma primeira an&#225;lise da mais importante associa&#231;&#227;o entre os escores de QDV (dimens&#227;o f&#237;sica, emocional e geral e escore global) e vari&#225;veis cont&#237;nuas. Considerando a correla&#231;&#227;o bivariada e a experi&#234;ncia cl&#237;nica, a an&#225;lise de regress&#227;o m&#250;ltipla foi realizada, tendo-se escolhido como vari&#225;veis explicativas G&#202;NERO, ETNIA, CF-NYHA, FE, DDVE, DSVE, CHARLSON, CVF%PREV, FEV1%PRE, VVM%PREV, ER e EAE. A colinearidade entre as vari&#225;veis da fun&#231;&#227;o pulmonar, particularmente na CVF e FEV1, s&#227;o conhecidas em situa&#231;&#227;o normal, embora estudos de pacientes com IC tenham mostrado conclus&#245;es variadas sobre elas<sup>18</sup>, variando de valores normais a altera&#231;&#245;es restritivas, a altera&#231;&#227;o restritiva e obstrutiva combinada<sup>18-20</sup>, e portanto, foram consideradas simultaneamente em um modelo multivariado. Na sequ&#234;ncia, a regress&#227;o backward stepwise para cada dimens&#227;o foi realizada a fim de estabelecer as vari&#225;veis mais influentes para essa amostra. Todas as regress&#245;es foram realizadas e acompanhadas de uma an&#225;lise de vari&#226;ncia para testar o poder de previs&#227;o da vari&#225;vel dependente. Um valor de p &lt; 0,05 foi considerado significante em compara&#231;&#245;es e correla&#231;&#245;es. G&#234;nero (Feminino=0 e Masculino=1), etnia (Caucasiano=0 e n&#227;o- Caucasiano=1), TD (0-2 anos=0 e 2+ anos=1), classe funcional (Classe I = 0 e Classe II / III= 1) foram consideradas mudas ("dummy") , para tornar a regress&#227;o m&#250;ltipla poss&#237;vel. </p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt01.jpg"/></table-wrap>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Dos 101 pacientes considerados para essa an&#225;lise, 74% eram do sexo masculino (n=76) e 26%, do feminino. A caracteriza&#231;&#227;o da amostra &#233; mostrada na <xref ref-type="table" rid="tab1">Tabela 1</xref>. </p>
    <p>
      <bold>Diferen&#231;as na QDV em vari&#225;veis categ&#243;ricas</bold>
    </p>
    <p>Nenhuma diferen&#231;a foi encontrada na QDV em rela&#231;&#227;o ao g&#234;nero em todos os escores nas dimens&#245;es, bem como no escore geral. Pacientes n&#227;o-Caucasianos (n=39) parecem ter uma QDV mais afetada no Escore Global (42,54&#177;20,47), quando comparados aos Caucasianos (n=62) (34,34&#177;16,38) para p=0,02863. Eles tamb&#233;m mostraram um escore maior na dimens&#227;o Geral: n&#227;o-Caucasianos (10,12&#177;6,2) <italic>versus</italic> Caucasianos (7,0&#177;5,3), p=0,008. As outras dimens&#245;es n&#227;o mostraram diferen&#231;as significantes. Em rela&#231;&#227;o ao TD, a amostra foi dividida em dois grupos (um grupo de 0 a 2 anos e um grupo com 2+ anos). Diferen&#231;as significantes foram observadas apenas na dimens&#227;o Emocional, onde o grupo 2+ anos apresentava piores valores de escore (16,07&#177;5) quando comparado com o grupo 0 a 2 anos (13,2&#177;8,2). Isso revela uma diminui&#231;&#227;o nos aspectos psicol&#243;gicos da pacientes com IC. Na <xref ref-type="table" rid="a15tab02m">Tabela 2</xref>, o teste de Kruskall Wallys mostrou diferen&#231;as significantes na QDV de acordo com a CF (NYHA). O teste <italic>post-hoc</italic> de Tukey mostrou que as Classes II e III n&#227;o apresentavam diferen&#231;as entre elas (p=ns), embora a Classe I tivesse melhores escores em todas as dimens&#245;es.</p>
    <p content-type="asset">
      <table-wrap id="a15tab02m">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt02.jpg"/></table-wrap>
    </p>
    <p>
      <bold>An&#225;lise de regress&#227;o m&#250;ltipla</bold>
    </p>
    <p>A fim de diferenciar vari&#225;veis importantes que t&#234;m uma correla&#231;&#227;o com a QDV, inicialmente foi feito um teste bivariado com cada vari&#225;vel cont&#237;nua e os escores do question&#225;rio de Minnesota. Esses resultados de correla&#231;&#227;o<sup>&#174;</sup> s&#227;o mostrados na <xref ref-type="table" rid="a15tab03m">Tabela 3</xref>. </p>
    <p content-type="asset">
      <table-wrap id="a15tab03m">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt03.jpg"/></table-wrap>
    </p>
    <p>Os par&#226;metros ecocardiogr&#225;ficos, espirom&#233;tricos e de comorbidades apresentaram &#237;ndices de correla&#231;&#227;o significantes e repetidos na maioria das dimens&#245;es da QDV. Em um caso isolado, a dimens&#227;o emocional apresentou uma correla&#231;&#227;o significante com idade e EAE, mostrando um pior estado emocional de acordo com o envelhecimento e a diminui&#231;&#227;o da capacidade de exerc&#237;cio. Ap&#243;s a identifica&#231;&#227;o dessas importantes correla&#231;&#245;es bivariadas, a an&#225;lise de regress&#227;o m&#250;ltipla foi realizada, excluindo aquelas que n&#227;o eram significantes. A literatura cient&#237;fica explica a import&#226;ncia da uni&#227;o entre o crit&#233;rio de signific&#226;ncia estat&#237;stica e pr&#225;tica<sup>21</sup>, ent&#227;o foi decidido adicionar algumas vari&#225;veis que n&#227;o fossem significantes em uma an&#225;lise univariada dessa amostra no modelo multivariado, respeitando a experi&#234;ncia cl&#237;nica, como o ERF e a EAE. Ap&#243;s v&#225;rios testes de regress&#227;o, as vari&#225;veis comuns selecionadas para as an&#225;lises multivariadas foram: G&#202;NERO, ETNIA, CF-NYHA, FE, DDVE, DSVE, CHARLSON, CVF, FEV1, VVM, ERF E EAE. Todas as vari&#225;veis foram simultaneamente correlacionadas &#224;s dimens&#245;es do question&#225;rio de Minnesota, neste caso considerado uma vari&#225;vel dependente. A <xref ref-type="table" rid="a15tab04m">Tabela 4</xref> mostra os n&#237;veis de signific&#226;ncia (p) de acordo com o n&#237;vel de correla&#231;&#227;o m&#250;ltipla (r e r<sup>2</sup>) de cada vari&#225;vel escolhida. N&#237;veis de p n&#227;o significantes foram indicados por <italic>"ns</italic>".</p>
    <p content-type="asset">
      <table-wrap id="a15tab04m">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt04.jpg"/></table-wrap>
    </p>
    <p>Vari&#225;veis categ&#243;ricas foram consideradas "mudas" como explicado em m&#233;todos. A fim de verificar a necessidade de deletar qualquer observa&#231;&#227;o de valor discrepante, uma an&#225;lise de res&#237;duos foi realizada e todos os casos foram distribu&#237;dos em &#177;3,5 res&#237;duos padronizados, de forma que n&#227;o foi necess&#225;rio excluir nenhum dado. Finalmente, uma an&#225;lise de regress&#227;o backward stepwise foi realizada para identificar a vari&#225;vel mais influente que contribui com o modelo multivari&#225;vel. A <xref ref-type="table" rid="a15tab05m">Tabela 5</xref> mostra os resultados da an&#225;lise de regress&#227;o backward stepwise das dimens&#245;es do question&#225;rio de Minnesota. </p>
    <p content-type="asset">
      <table-wrap id="a15tab05m">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt05.jpg"/></table-wrap>
    </p>
    <p>Sob cada dimens&#227;o &#233; poss&#237;vel visualizar os valores de R e R<sup>2</sup>, onde R representa a correla&#231;&#227;o das vari&#225;veis (dependente <italic>versus</italic> independente) e R<sup>2</sup> representa um coeficiente de regress&#227;o em um n&#237;vel espec&#237;fico de signific&#226;ncia para um tamanho de amostra espec&#237;fico. Nesse estudo, os achados mais importantes estavam relacionados com os escores globais do question&#225;rio de Minnesota, onde 7 vari&#225;veis independentes podiam explicar de forma consistente 60% dos resultados (g&#234;nero, etnia, DSVE, ERF, CVF, FEV1, VVM). As outras dimens&#245;es apresentaram associa&#231;&#245;es significantes mais fracas.</p>
    <p>Uma an&#225;lise de vari&#226;ncia ap&#243;s o modelo inicial multivariado e ap&#243;s a regress&#227;o backward stepwise mostrou que as vari&#225;veis independentes podiam explicar os escores das dimens&#245;es do question&#225;rio de Minnesota (p&lt;0,05). Tamb&#233;m realizamos o F-teste para cada regress&#227;o a fim de testar a signific&#226;ncia de R, o que &#233; o mesmo que testar a signific&#226;ncia de R<sup>2. </sup>Todas as an&#225;lises mostraram valores significantes para R e R<sup>2</sup>. Especificamente para Escores Globais, a regress&#227;o stepwise &#233; utilizada na fase explorat&#243;ria de pesquisa ou com prop&#243;sito de pura predi&#231;&#227;o; esta rela&#231;&#227;o &#233; mostrada em forma de gr&#225;fico na <xref ref-type="fig" rid="fig1">Figura 1</xref>. </p>
    <fig id="fig1">
      <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gf01.jpg"/></fig>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>IC &#233; uma disfun&#231;&#227;o multifatorial que diminui o estado funcional; ela requer hospitaliza&#231;&#245;es frequentes e afeta a expectativa de vida do paciente. Quase 5 milh&#245;es de pessoas vivem com IC, e 550.000 novos casos s&#227;o diagnosticados a cada ano<sup>22</sup>. Especificamente no Brasil, a doen&#231;a resulta em altos gastos para o paciente e para o sistema p&#250;blico de sa&#250;de<sup>4,23</sup>. Ao analisar as causas cl&#237;nicas respons&#225;veis pelo alto n&#250;mero de hospitaliza&#231;&#245;es em 2002 sob a responsabilidade do Sistema &#218;nico de Sa&#250;de (SUS) brasileiro, a IC ficou em terceiro lugar (372.604), ap&#243;s pneumonia (794.260) e asma (376.447)<sup>4</sup>. Estrat&#233;gias para melhorar resultados enfocando n&#227;o apenas desfechos objetivos e fisiol&#243;gicos s&#227;o primordiais para o seu manejo, objetivando resultados mais amplos<sup>24,25</sup>. A QDV na IC ainda &#233; um complexo objeto de estudo e mesmo no presente, ainda n&#227;o est&#225; bem estabelecido. Muitos aspectos podem influenciar sua avalia&#231;&#227;o (aspectos biopsicossociais), e estes pontos estimulam sua investiga&#231;&#227;o. O presente estudo sugere que a QDV na IC deve ser analisada atrav&#233;s de uma vis&#227;o multiangular. Isso pode ser observado nas associa&#231;&#245;es dos escores Globais, onde sete vari&#225;veis distintas independentes podem explicar cerca de 60% dos resultados de QDV da amostra quando analisadas simultaneamente. A etnia &#233; um dos fatores a ser considerado em nosso estudo. Pacientes n&#227;o-Caucasianos apresentam uma QDV pior quando comparados aos Caucasianos. A literatura explica que h&#225; diferen&#231;as entre as etnias na preval&#234;ncia, etiologia e desfechos da IC<sup>26</sup>. Como mencionado por Taylor e cols.<sup>27</sup>, quando comparados aos Caucasianos, os Afro-americanos apresentam taxas acentuadamente mais altas de diagn&#243;stico de IC, t&#234;m maior probabilidade de hipertens&#227;o do que doen&#231;a arterial coronariana, morrem mais rapidamente e s&#227;o hospitalizados mais frequentemente devido &#224; IC. Mesmo com os avan&#231;os da terapia card&#237;aca nos Estados Unidos, eles n&#227;o se beneficiam de forma equivalente; por exemplo, pacientes afro-descendentes n&#227;o respondem t&#227;o bem &#224; a&#231;&#227;o do inibidor de enzima conversora da angiotensina (IECA)<sup>28</sup>. N&#227;o h&#225; estudos com a popula&#231;&#227;o afro-descendente brasileira, mas o mesmo mecanismo parece estar envolvido. Adicionalmente, diferen&#231;as &#233;tnicas podem estar relacionadas n&#227;o somente ao manejo da IC ou sua fisiopatologia, mas concomitantemente aos sistemas de sa&#250;de e social brasileiros, onde o negro tem menos condi&#231;&#245;es de acesso para preven&#231;&#227;o e tratamento de v&#225;rias doen&#231;as<sup>29,30</sup>. A Classifica&#231;&#227;o Funcional da NYHA &#233; um esquema de classifica&#231;&#227;o geral derivada do fornecedor amplamente utilizado para categorizar pacientes em termos de sintomas associados com as atividades di&#225;rias. Nosso estudo, bem como outros, mostrou diferen&#231;as significantes nas classes funcionais da NYHA quando QDV foi comparada entre elas. Bennet e cols.<sup>31</sup>, encontraram diferen&#231;as na QDV, com exce&#231;&#227;o das classes III e IV. O presente estudo n&#227;o levou em considera&#231;&#227;o a classe IV devido &#224;s dificuldades t&#233;cnicas na realiza&#231;&#227;o de alguns testes, tais como espirometria, que causa extrema dispn&#233;ia em pacientes de classe IV. Foi observado que assim como nas classes NYHA, pacientes de classe I apresentavam menos impacto evidente na sua QDV. A an&#225;lise multivariada mostrou que a Classifica&#231;&#227;o Funcional da NYHA &#233; uma vari&#225;vel de influ&#234;ncia importante na QDV dos pacientes, especificamente nos Escores Global e Dimens&#227;o Emocional. A Classifica&#231;&#227;o Funcional da NYHA mostrou uma rela&#231;&#227;o significante com vitalidade e sa&#250;de mental em um estudo usando SF-36<sup>5</sup>, sugerindo que as Classes NYHA devem ser avaliadas levando-se em considera&#231;&#227;o n&#227;o apenas os aspectos f&#237;sicos, mas tamb&#233;m os subjetivos. As correla&#231;&#245;es bivariadas demonstraram uma associa&#231;&#227;o baixa, por&#233;m significante, entre os par&#226;metros ecocardiogr&#225;ficos tais como FE, DDVE e DSVE, mostrando que a capacidade de d&#233;bito card&#237;aco deficiente e di&#226;metro sist&#243;lico e diast&#243;lico aumentado do ventr&#237;culo esquerdo causado por sobrecarga poderiam prejudicar a QDV. Myers e cols.<sup>32</sup>, usando outro instrumento de avalia&#231;&#227;o de QDV demonstraram uma fraca, mas significante correla&#231;&#227;o entre FE e QDV<sup>32</sup>. Mitani e cols.<sup>5</sup>, usando um instrumento gen&#233;rico de avalia&#231;&#227;o (SF-36)<sup>33</sup>, n&#227;o observaram nenhuma associa&#231;&#227;o entre esses par&#226;metros. Em um estudo importante para essa &#225;rea, Grigioni e cols.<sup>24</sup>, usando o question&#225;rio de Minnesota, tamb&#233;m n&#227;o encontraram nenhuma associa&#231;&#227;o entre o ecocardiograma e os par&#226;metros de QDV; entretanto, eles levaram em considera&#231;&#227;o as classes NYHA I a IV. &#201; interessante o fato de que, quando realizamos a an&#225;lise multivariada, apenas o DSVE permaneceu como um fator de influ&#234;ncia geral na QDV. Estudos adicionais seriam importantes para esclarecer esses pontos. </p>
    <p>O &#205;ndice de Comorbidade de Chalson<sup>9,34</sup> mostra um progn&#243;stico baseado na idade e condi&#231;&#245;es de comorbidade; com cada n&#237;vel aumentado do &#237;ndice de comorbidade, a mortalidade cumulativa atribu&#237;vel &#224; doen&#231;a com&#243;rbida aumenta de forma gradual. Em nosso estudo, as comorbidades tiveram uma correla&#231;&#227;o bivariada significante com a QDV e embora o modelo multivariado n&#227;o tenha mostrado signific&#226;ncia estat&#237;stica, pudemos observar uma tend&#234;ncia (p=0,082518). A comorbidade em pacientes com IC pode contribuir para as dificuldades diagn&#243;sticas em pacientes mais velhos<sup>35</sup> e est&#225; diretamente associada ao progn&#243;stico quando se considera a mortalidade<sup>36</sup>. H&#225; falta de estudos espec&#237;ficos que relacionem a QDV na IC e as comorbidades. O ERF demonstrou ser um importante aspecto a ser considerado ao avaliar a QDV na IC, j&#225; que seus m&#250;ltiplos escores levam em considera&#231;&#227;o n&#227;o apenas o impacto das vari&#225;veis espec&#237;ficas como idade, colesterol, press&#227;o arterial e fumo, mas tamb&#233;m o sinergismo entre elas<sup>11</sup>. Sua presen&#231;a no modelo backward stepwise mostrou a import&#226;ncia da experi&#234;ncia cl&#237;nica na avalia&#231;&#227;o de pacientes com IC. </p>
    <p>O presente estudo mostrou que a fun&#231;&#227;o pulmonar estava diminu&#237;da e que isso tinha uma rela&#231;&#227;o importante com a QDV dos pacientes. A correla&#231;&#227;o bivariada mostrou que escores mais altos no question&#225;rio de Minnesota apresentavam resultados piores na espirometria. CVF e FEV1 diminu&#237;dos e raz&#227;o FEV 1/CVF normal foram observados na amostra e isto &#233; corroborado por Johnson e cols.<sup>18</sup> e Forgiarini e cols.<sup>19</sup>; entretanto, outros estudos n&#227;o relacionaram disfun&#231;&#227;o pulmonar e QDV na IC. Outro aspecto importante a ser evidenciado &#233; que pelo menos um par&#226;metro de fun&#231;&#227;o pulmonar estava associado &#224; QDV (dimens&#245;es). Os valores respirat&#243;rios anormais poderiam ser atribu&#237;dos &#224; fatores musculares<sup>19,37-39</sup>, o que pode explicar os sintomas de falta de ar e a redu&#231;&#227;o na capacidade de exerc&#237;cio al&#233;m da posi&#231;&#227;o do diafragma que est&#225; alterada na IC e que causa uma desvantagem mec&#226;nica na efic&#225;cia respirat&#243;ria como resultado de uma resposta adaptativa &#224; altera&#231;&#227;o na raz&#227;o cardiotor&#225;cica pelo deslocamento mec&#226;nico direto do diafragma devido ao aumento do cora&#231;&#227;o<sup>40</sup>.</p>
    <p>O achado mais importante desse estudo est&#225; relacionado aos efeitos simult&#226;neos das vari&#225;veis e da QDV dos pacientes na an&#225;lise multivariada. Considerando todas as correla&#231;&#245;es bivariadas relacionadas &#224;s vari&#225;veis da QDV mais as vari&#225;veis baseadas em experi&#234;ncia pr&#225;tica, foi demonstrado um R<sup>2</sup>= 0,64 e ap&#243;s a aplica&#231;&#227;o do modelo backward stepwise, obtivemos um R<sup>2</sup>= 0,60. O modelo backward stepwise &#233; um m&#233;todo de busca sequencial que come&#231;a com todas as vari&#225;veis e elimina aquelas que s&#227;o independentes uma de cada vez, at&#233; que a elimina&#231;&#227;o de uma resulta em uma diferen&#231;a significante no R ao quadrado. Em nosso caso, selecionamos vari&#225;veis explicativas que proviam bons preditores de QDV, tais como g&#234;nero, etnia, DSVE, ERF, CVF, FEV1, VVM (<xref ref-type="table" rid="a15tab04m">Tabela 4</xref>). </p>
    <p>Em rela&#231;&#227;o &#224;s limita&#231;&#245;es do estudo, pode ser observado que as vari&#225;veis estudadas ainda falham em detectar cerca de 40% da vari&#226;ncia da QDV e isso pode estar relacionado n&#227;o apenas &#224;s vari&#225;veis objetivas, mas &#224; outros aspectos da doen&#231;a que n&#227;o puderam ser encontrados no presente estudo; ainda assim, este estudo &#233; o primeiro passo na tentativa de correlacionar um aspecto t&#227;o importante e pouco entendido da avalia&#231;&#227;o da IC e acreditamos que estudos futuros com amostras maiores e a inclus&#227;o de outras vari&#225;veis independentes, como por exemplo fumo, pr&#225;tica de exerc&#237;cios e lazer, apoio psicol&#243;gico e outras possam explicar as grandes varia&#231;&#245;es na QDV. </p>
    <p>Em conclus&#227;o, g&#234;nero, etnia, DSVE, ERF, CVF, FEV1 e VVM podem ser considerados preditores independentes da QDV em pacientes cm IC; juntas, elas representam cerca de 60% da vari&#226;ncia da QDV. Este estudo demonstra que a QDV est&#225; afetada em pacientes com IC e que &#233; importante lev&#225;-la em considera&#231;&#227;o no manejo da doen&#231;a. Outros aspectos al&#233;m dos objetivos tamb&#233;m s&#227;o fundamentais na vida di&#225;ria do paciente com IC. O presente estudo aconselha os profissionais da sa&#250;de a n&#227;o enfatizarem apenas os resultados fisiol&#243;gicos, mas tamb&#233;m levar em conta os aspectos hol&#237;sticos tais como influ&#234;ncias psicol&#243;gicas e funcionalidade, as quais podem afetar o estado geral do paciente. </p>
    <p>
      <bold>Agradecimentos</bold>
    </p>
    <p>O estudo foi conduzido com o apoio da Universidade do Paran&#225; (Brasil) e do Programa de Doutorado em Ci&#234;ncias da Sa&#250;de da Universidade Cat&#243;lica do Paran&#225; (Brasil).</p>
    <p>Agradecemos ao Prof. Dr. Roberto Pecoits Filho e &#224; Dr&#170;. Fabiane Nascimento por suas sugest&#245;es &#250;teis ao pr&#233;-projeto do estudo. </p>
    <p>Os autores agradecem &#224; Prof&#170;. Marcia Olandoski pela ajuda com a an&#225;lise estat&#237;stica.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi parcialmente financiado pelo Programa de Capacita&#231;&#227;o Docente da Universidade Paranaense - UNIPAR.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Jefferson J. Amaral dos Santos pela Pont&#237;fica Universidade Cat&#243;lica do Paran&#225;.</p>
    <p>
      <fn id="not1" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Jefferson Jovelino Amaral dos Santos </p>
        <p> Av. Tiradentes, 1001 / 12 </p>
        <p> 85900-230 - Toledo, PR, Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="jeffe_fisio@yahoo.com.br">jeffe_fisio@yahoo.com.br</email> , </p>
        <p>
          <email xlink:href="jeffe@unipar.br">jeffe@unipar.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 16/03/08; revisado recebido em 06/10/08; aceito em 24/10/08</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. WHOQOL Group. The development of the World Health Organization quality of life assessment instrument (the WHOQOL). In: Orley J, Kuyken W. (eds.). Quality of life assessment: international perspectives. Heidelberg: Springer Verlag; 1994. p. 41-60.</mixed-citation>
        <element-citation publication-type="book">
          <source>Quality of life assessment: international perspectives</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>41</fpage>
          <lpage>60</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Orley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kuyken</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002; 23: 1867-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1867</fpage>
          <lpage>76</lpage>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hobbs</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Kenkre</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Roalfe</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Hare</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22 (17): 1527-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines for the diagnosis and treatment of chronic heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1527</fpage>
          <lpage>60</lpage>
          <issue>17</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Remme</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Albanesi Filho FM. What is the current scenario for heart failure in Brazil?. Arq Bras Cardiol. 2005; 85 (3): 155-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>What is the current scenario for heart failure in Brazil?</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>155</fpage>
          <lpage>6</lpage>
          <issue>3</issue>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Albanesi Filho</surname>
              <given-names>FM.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Mitani H, Hashimoto H, Isshiki T, Kurokawa S, Ogawa K, Matsumoto K, et al. Health-related quality of life of Japanese patients with chronic heart failure: assessment using the Medical Outcome Study Short Form 36. Circ J. 2003; 67 (3): 215-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Health-related quality of life of Japanese patients with chronic heart failure: assessment using the Medical Outcome Study Short Form 36</article-title>
          <source>Circ J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>215</fpage>
          <lpage>20</lpage>
          <issue>3</issue>
          <volume>67</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mitani</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Isshiki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kurokawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Sociedade Brasileira de Cardiologia. Revis&#227;o das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca. Arq Bras Cardiol. 2002; 79 (supl. 4): 1-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Revis&#227;o das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>30</lpage>
          <volume>79</volume>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Alla F, Briancon S, Guillemin F, Juilliere Y, Mertes PM, Villemot JP, et al. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Fail. 2002; 4 (3): 337-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>337</fpage>
          <lpage>43</lpage>
          <issue>3</issue>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alla</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Briancon</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guillemin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Juilliere</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mertes</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Villemot</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981; 64 (6): 1227-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale</article-title>
          <source>Circulation</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>1227</fpage>
          <lpage>34</lpage>
          <issue>6</issue>
          <volume>64</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Goldman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Loscalzo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47 (11): 1245-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Validation of a combined comorbidity index</article-title>
          <source>J Clin Epidemiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1245</fpage>
          <lpage>51</lpage>
          <issue>11</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Charlson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Szatrowski</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Sociedade Brasileira de Cardiologia. III Diretrizes brasileiras sobre dislipidemias e Diretriz de preven&#231;&#227;o de aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2001; 77 (supl. 3): 1-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretrizes brasileiras sobre dislipidemias e Diretriz de preven&#231;&#227;o de aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1</fpage>
          <lpage>48</lpage>
          <volume>77</volume>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Sociedade Brasileira de Cardiologia. IV Diretrizes brasileiras em dislipidemias e guia de preven&#231;&#227;o de aterosclerose. Arq Bras Cardiol. 2007; 88 (supl. 1): 2-19.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>IV Diretrizes brasileiras em dislipidemias e guia de preven&#231;&#227;o de aterosclerose</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2</fpage>
          <lpage>19</lpage>
          <volume>88</volume>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26 (2): 319-38.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Standardisation of spirometry</article-title>
          <source>Eur Respir J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>319</fpage>
          <lpage>38</lpage>
          <issue>2</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Hankinson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brusasco</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Burgos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Casaburi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coates</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Pereira CAC, Barreto SP, Sim&#246;es JG, Pereira FWL, Gerstler JG, Nakatani J. Valores de refer&#234;ncia para a espirometria em uma amostra da popula&#231;&#227;o brasileira adulta. J Pneumol. 1992; 18 (1): 10-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Valores de refer&#234;ncia para a espirometria em uma amostra da popula&#231;&#227;o brasileira adulta</article-title>
          <source>J Pneumol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>10</fpage>
          <lpage>22</lpage>
          <issue>1</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>CAC</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Sim&#246;es</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>FWL</given-names>
            </name>
            <name>
              <surname>Gerstler</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Nakatani</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985; 41 (4): 810-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of fat-free mass using bioelectrical impedance measurements of the human body</article-title>
          <source>Am J Clin Nutr</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>810</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lukaski</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Bolonchuk</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Lykken</surname>
              <given-names>GI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Rector TS, Kubo S., Cohn J. Patient's self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. Heart Fail. 1987; 3: 198-209.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Patient's self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire</article-title>
          <source>Heart Fail</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>198</fpage>
          <lpage>209</lpage>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rector</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Carrara D. Avalia&#231;&#227;o prospectiva da qualidade de vida em pacientes com miocardiopatia dilatada submetidos a ventriculectomia parcial esquerda [;Disserta&#231;&#227;o];. S&#227;o Paulo: Universidade de S&#227;o Paulo; 2001.</mixed-citation>
        <element-citation publication-type="thesis">
          <source>Avalia&#231;&#227;o prospectiva da qualidade de vida em pacientes com miocardiopatia dilatada submetidos a ventriculectomia parcial esquerda</source>
          <date>
            <year>2001</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Carrara</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Saccomann IC, Cintra FA, Gallani MC. Psychometric properties of the Minnesota Living with Heart Failure--Brazilian version--in the elderly. Qual Life Res. 2007; 16 (6): 997-1005.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Psychometric properties of the Minnesota Living with Heart Failure--Brazilian version--in the elderly</article-title>
          <source>Qual Life Res</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>997</fpage>
          <lpage>1005</lpage>
          <issue>6</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Saccomann</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Cintra</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Gallani</surname>
              <given-names>MC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Johnson BD, Beck KC, Olson LJ, O'Malley KA, Allison TG, Squires RW, et al. Pulmonary function in patients with reduced left ventricular function: influence of smoking and cardiac surgery. Chest. 2001; 120 (6): 1869-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pulmonary function in patients with reduced left ventricular function: influence of smoking and cardiac surgery</article-title>
          <source>Chest</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1869</fpage>
          <lpage>76</lpage>
          <issue>6</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Squires</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Forgiarini LA Jr., Rubleski A, Douglas G, Tieppo J, Vercelino R, Dal Bosco A, et al. Evaluation of respiratory muscle strength and pulmonary function in heart failure patients. Arq Bras Cardiol. 2007; 89 (1): 36-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of respiratory muscle strength and pulmonary function in heart failure patients</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>36</fpage>
          <lpage>41</lpage>
          <issue>1</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Forgiarini Jr</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Rubleski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tieppo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vercelino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dal Bosco</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Wright RS, Levine MS, Bellamy PE, Simmons MS, Batra P, Stevenson LW, et al. Ventilatory and diffusion abnormalities in potential heart transplant recipients. Chest. 1990; 98 (4): 816-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventilatory and diffusion abnormalities in potential heart transplant recipients</article-title>
          <source>Chest</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>816</fpage>
          <lpage>20</lpage>
          <issue>4</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Bellamy</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Batra</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Hair JF, Black B, Babin B, Anderson RE, Tatham RL. Multivariate data analysis. 5<sup>th</sup> ed. New Jersey: Prentice Hall; 1998.</mixed-citation>
        <element-citation publication-type="book">
          <source>Multivariate data analysis</source>
          <date>
            <year>1998</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Hair</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Babin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Tatham</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Association AH. Understanding Heart Failure.  2007  [;cited 2007 september];; Available from: <ext-link ext-link-type="uri" xlink:href="http://www.americanheart.org/presenter.jhtml?identifier=1486">http://www.americanheart.org/presenter.jhtml?identifier=1486</ext-link></mixed-citation>
        <element-citation publication-type="book">
          <source>Understanding Heart Failure</source>
          <date>
            <year>2007</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Araujo DV, Tavares LR, Verissimo R, Ferraz MB, Mesquita ET. Cost of heart failure in the Unified Health System. Arq Bras Cardiol. 2005; 84 (5): 422-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cost of heart failure in the Unified Health System</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>422</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Araujo</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Tavares</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Verissimo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Grigioni F, Carigi S, Grandi S, Potena L, Coccolo F, Bacchi-Reggiani L, et al. Distance between patients' subjective perceptions and objectively evaluated disease severity in chronic heart failure. Psychother Psychosom. 2003; 72 (3): 166-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Distance between patients' subjective perceptions and objectively evaluated disease severity in chronic heart failure</article-title>
          <source>Psychother Psychosom</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>166</fpage>
          <lpage>70</lpage>
          <issue>3</issue>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grigioni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Carigi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grandi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Potena</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Coccolo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bacchi-Reggiani</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Michalsen A, Grossman P, Lehmann N, Knoblauch NT, Paul A, Moebus S, et al. Psychological and quality-of-life outcomes from a comprehensive stress reduction and lifestyle program in patients with coronary artery disease: results of a randomized trial. Psychother Psychosom. 2005; 74 (6): 344-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Psychological and quality-of-life outcomes from a comprehensive stress reduction and lifestyle program in patients with coronary artery disease: results of a randomized trial</article-title>
          <source>Psychother Psychosom</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>344</fpage>
          <lpage>52</lpage>
          <issue>6</issue>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Michalsen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Knoblauch</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moebus</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005; 96 (7B): 44-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The African American Heart Failure Trial: a clinical trial update</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>44</fpage>
          <lpage>8</lpage>
          <issue>7B</issue>
          <volume>96</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Taylor AL, Cohn JN, Worcel M, Franciosa JA. The African-American Heart Failure Trial: background, rationale and significance. J Natl Med Assoc. 2002; 94 (9): 762-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The African-American Heart Failure Trial: background, rationale and significance</article-title>
          <source>J Natl Med Assoc</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>762</fpage>
          <lpage>9</lpage>
          <issue>9</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Worcel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Franciosa</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Cohn JN. The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial. J Law Med Ethics. 2006; 34 (3): 552-4, 480.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial</article-title>
          <source>J Law Med Ethics</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>552</fpage>
          <lpage>4</lpage>
          <issue>3</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cohn</surname>
              <given-names>JN.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Barata RB, Almeida MF, Montero CV, Silva ZP. Health inequalities based on ethnicity in individuals aged 15 to 64, Brazil, 1998. Cad Saude Publica. 2007; 23 (2): 305-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Health inequalities based on ethnicity in individuals aged 15 to 64, Brazil, 1998</article-title>
          <source>Cad Saude Publica</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>305</fpage>
          <lpage>13</lpage>
          <issue>2</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barata</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Montero</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>ZP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Heringer R. Racial inequalities in Brazil: a synthesis of social indicators and challenges for public policies. Cad Sa&#250;de Publica. 2002;18 (supl): 57-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Racial inequalities in Brazil: a synthesis of social indicators and challenges for public policies</article-title>
          <source>Cad Sa&#250;de Publica</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>57</fpage>
          <lpage>65</lpage>
          <issue>supl</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Heringer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Bennet SJ, Oldridge NB, Eckert GJ, Embree JL, Browning S, Hou N, et al. Discriminant properties of commonly used quality of life measures in heart failure. Qual Life Res. 2002; 11 (4): 349-59.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Discriminant properties of commonly used quality of life measures in heart failure</article-title>
          <source>Qual Life Res</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>349</fpage>
          <lpage>59</lpage>
          <issue>4</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bennet</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Oldridge</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Eckert</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Embree</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Browning</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hou</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Myers J, Zaheer N, Quaglietti S, Madhavan R, Froelicher V, Heidenreich P. Association of functional and health status measures in heart failure. J Card Fail. 2006; 12 (6): 439-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of functional and health status measures in heart failure</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>439</fpage>
          <lpage>45</lpage>
          <issue>6</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Myers</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zaheer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Quaglietti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Madhavan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Heidenreich</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30 (6): 473-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection</article-title>
          <source>Med Care</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>473</fpage>
          <lpage>83</lpage>
          <issue>6</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ware Jr</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Sherbourne</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title>
          <source>J Chronic Dis</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>373</fpage>
          <lpage>83</lpage>
          <issue>5</issue>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Charlson</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Pompei</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ales</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ. 2003; 326 (7382): 196.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study</article-title>
          <source>BMJ</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>196</fpage>
          <issue>7382</issue>
          <volume>326</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fuat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hungin</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart.  2003; 89 (6): 615-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001</article-title>
          <source>Heart</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>615</fpage>
          <lpage>20</lpage>
          <issue>6</issue>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Blackledge</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Tomlinson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Squire</surname>
              <given-names>IB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Hughes PD, Polkey MI, Harrus ML, Coats AJ, Moxham J, Green M. Diaphragm strength in chronic heart failure. Am J Respir Crit Care Med. 1999; 160 (2): 529-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diaphragm strength in chronic heart failure</article-title>
          <source>Am J Respir Crit Care Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>529</fpage>
          <lpage>34</lpage>
          <issue>2</issue>
          <volume>160</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hughes</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Polkey</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Harrus</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Moxham</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Darnley GM, Gray AC, McClure SJ, Neary P, Petrie M, McMurray JJ, et al. Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. Eur J Heart Fail. 1999; 1 (3): 297-300.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>297</fpage>
          <lpage>300</lpage>
          <issue>3</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Darnley</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>McClure</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Neary</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Petrie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Johnson BD, Beck KC, Olson LJ, O'Malley KA, Allison TG, Squires RW, et al. Ventilatory constraints during exercise in patients with chronic heart failure. Chest. 2000; 117 (2): 321-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventilatory constraints during exercise in patients with chronic heart failure</article-title>
          <source>Chest</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>321</fpage>
          <lpage>32</lpage>
          <issue>2</issue>
          <volume>117</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>O'Malley KA</surname>
            </name>
            <name>
              <surname>Allison</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Squires</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Caruana L, Petrie MC, McMurray JJ, MacFarlane NG. Altered diaphragm position and function in patients with chronic heart failure. Eur J Heart Fail. 2001; 3 (2): 183-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Altered diaphragm position and function in patients with chronic heart failure</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>183</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Caruana</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Petrie</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>MacFarlane</surname>
              <given-names>NG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Calidad de vida e indicadores cl&#237;nicos en la insuficiencia cardiaca: an&#225;lisis multivariado</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: En la insuficiencia cardiaca (IC), la atenci&#243;n especial es necesaria no solamente en cuanto a aspectos objetivos o aislados, sino tambi&#233;n a las percepciones de la salud del paciente. Los aspectos subjetivos pueden ayudar a los profesionales de la salud a comprender a tratar mejor la IC. OBJETIVO: El objetivo de ese estudio fue evaluar simult&#225;neamente los efectos de los indicadores cl&#237;nicos de la IC en la calidad de vida (CDV). M&#201;TODOS: Investigamos, por medio de an&#225;lisis multivariado, la CDV de 101 pacientes ambulatorios brasile&#241;os, con la utilizaci&#243;n del cuestionario de Minnesota (Minnesota Living with Heart Failure Questionnaire), incluyendo sus subescalas y su correlaci&#243;n con las variables cl&#237;nicas y psicol&#243;gicas, tales como edad, etnia, g&#233;nero, par&#225;metros ecocardiogr&#225;ficos, &#237;ndice de masa corporal, presi&#243;n arterial promedio de reposo, tiempo de diagn&#243;stico, Clasificaci&#243;n Funcional de acuerdo con la NYHA, capacidad funcional a trav&#233;s de una Escala de Actividad Espec&#237;fica, comorbilidades, Score de Riesgo de Framingham (ERF), prueba de funci&#243;n pulmonar (espirometr&#237;a) y composici&#243;n corporal. RESULTADOS: La CDV present&#243; correlaciones univariadas significantes con el ecocardiograma: fracci&#243;n de eyecci&#243;n (p=0,0415), di&#225;metro diast&#243;lico del ventr&#237;culo izquierdo (DDVI) (p=0,004), di&#225;metro sist&#243;lico del ventr&#237;culo izquierdo (DSVI) (p=0,0001); comorbilidades (p=0,002) y prueba de funci&#243;n pulmonar: Capacidad Vital Forzada (CVF) (p&lt;0,0001), Volumen Espiratorio Forzado en el 1er segundo (FEV1) (p&lt;0,0001) y Ventilaci&#243;n Voluntaria M&#225;xima (VVM) (p=0,001). En el an&#225;lisis multivariado, el protocolo Backward Stepwise detect&#243; importantes variables influyentes simult&#225;neas (r&#178;=0.60): g&#233;nero (0,000178), etnia (p&lt;0,00001), DSVI (P&lt;0.00001), ERF (p=0,000002), CVF (p=0,002027), FEV1 (p&lt;0,00001) y VVM (p=0,00001). CONCLUSI&#211;N: G&#233;nero, etnia, DSVI, ERF, CVF, FEV1 y VVM son predictores independientes de CDV en pacientes con IC. Simult&#225;neamente, ellos son responsables por cerca del 60% de la variancia de la CDV. Los aspectos biopsicosociales pueden contribuir a las expectativas de los pacientes y profesionales de salud y resultado del tratamiento.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia cardiaca</kwd>
        <kwd>calidad de vida</kwd>
        <kwd>salud hol&#237;stica</kwd>
        <kwd>an&#225;lisis multivariado</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="inicio-body2"/>Calidad de vida e indicadores cl&#237;nicos en la insuficiencia cardiaca: an&#225;lisis multivariado</p>
      <p>
        <bold>Jefferson Jovelino Amaral dos Santos<sup>I</sup>; Jony Erwin Andreola Plewka<sup>II</sup>; Paulo Roberto Slud Brofmanv<sup>III</sup></bold>
      </p>
      <p><sup>I</sup>Universidade Paranaense (UNIPAR), Toledo, PR</p>
      <p><sup>II</sup>Instituto de Cardiologia de Toledo, Toledo, PR</p>
      <p><sup>III</sup>Programa de Doutorado em Ci&#234;ncias da Sa&#250;de (PUCPR), Curitiba, PR - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> En la insuficiencia cardiaca (IC), la atenci&#243;n especial es necesaria no solamente en cuanto a aspectos objetivos o aislados, sino tambi&#233;n a las percepciones de la salud del paciente. Los aspectos subjetivos pueden ayudar a los profesionales de la salud a comprender a tratar mejor la IC. </p>
      <p><bold>OBJETIVO:</bold> El objetivo de ese estudio fue evaluar simult&#225;neamente los efectos de los indicadores cl&#237;nicos de la IC en la calidad de vida (CDV).</p>
      <p><bold>M&#201;TODOS:</bold> Investigamos, por medio de an&#225;lisis multivariado, la CDV de 101 pacientes ambulatorios brasile&#241;os, con la utilizaci&#243;n del cuestionario de Minnesota (<italic>Minnesota Living with Heart Failure Questionnaire</italic>), incluyendo sus subescalas y su correlaci&#243;n con las variables cl&#237;nicas y psicol&#243;gicas, tales como edad, etnia, g&#233;nero, par&#225;metros ecocardiogr&#225;ficos, &#237;ndice de masa corporal, presi&#243;n arterial promedio de reposo, tiempo de diagn&#243;stico, Clasificaci&#243;n Funcional de acuerdo con la NYHA, capacidad funcional a trav&#233;s de una Escala de Actividad Espec&#237;fica, comorbilidades, Score de Riesgo de Framingham (ERF), prueba de funci&#243;n pulmonar (espirometr&#237;a) y composici&#243;n corporal. </p>
      <p><bold>RESULTADOS:</bold> La CDV present&#243; correlaciones univariadas significantes con el ecocardiograma: fracci&#243;n de eyecci&#243;n (p=0,0415), di&#225;metro diast&#243;lico del ventr&#237;culo izquierdo (DDVI) (p=0,004), di&#225;metro sist&#243;lico del ventr&#237;culo izquierdo (DSVI) (p=0,0001); comorbilidades (p=0,002) y prueba de funci&#243;n pulmonar: Capacidad Vital Forzada (CVF) (p&lt;0,0001), Volumen Espiratorio Forzado en el 1er segundo (FEV1) (p&lt;0,0001) y Ventilaci&#243;n Voluntaria M&#225;xima (VVM) (p=0,001). En el an&#225;lisis multivariado, el protocolo Backward Stepwise detect&#243; importantes variables influyentes simult&#225;neas (r2=0.60): g&#233;nero (0,000178), etnia (p&lt;0,00001), DSVI (P&lt;0.00001), ERF (p=0,000002), CVF (p=0,002027), FEV1 (p&lt;0,00001) y VVM (p=0,00001). </p>
      <p><bold>CONCLUSI&#211;N:</bold> G&#233;nero, etnia, DSVI, ERF, CVF, FEV1 y VVM son predictores independientes de CDV en pacientes con IC. Simult&#225;neamente, ellos son responsables por cerca del 60% de la variancia de la CDV. Los aspectos biopsicosociales pueden contribuir a las expectativas de los pacientes y profesionales de salud y resultado del tratamiento. </p>
      <p><bold>Palabras clave:</bold> Insuficiencia cardiaca, calidad de vida, salud hol&#237;stica, an&#225;lisis multivariado.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La evaluaci&#243;n de la calidad de vida (CDV) ha se convertido en indispensable al evaluarse un paciente en la pr&#225;ctica cl&#237;nica. La Organizaci&#243;n Mundial de Salud (OMS) define la CDV como "la percepci&#243;n del individuo con relaci&#243;n a su posici&#243;n en la vida seg&#250;n el contexto cultural y los sistemas de valores en los que &#233;l vive y en cuanto a sus objetivos, expectativas, est&#225;ndares y preocupaciones"<sup>1</sup>. </p>
      <p>La insuficiencia cardiaca (IC) es un s&#237;ndrome cl&#237;nico resultante de un disturbio card&#237;aco funcional o estructural que perjudica la capacidad del ventr&#237;culo de llenarse con sangre o de eyectarse de sangre suficiente conforme la demanda del cuerpo, o permite hacerlo s&#243;lo con presiones de relleno aumentadas. Se estima su prevalencia en aproximadamente un 2,3% en la poblaci&#243;n general<sup>2</sup> y del 0,4% al 2% en la poblaci&#243;n europea<sup>3</sup>; aproximadamente de 5 millones de personas en los EUA tienen IC y la condici&#243;n resulta en cerca de 300 mil muertes todos los a&#241;os. En el Brasil, el mayor pa&#237;s de Sudam&#233;rica, la IC es la tercera causa de todas las hospitalizaciones<sup>4</sup>. La IC no es solamente una enfermedad de poblaci&#243;n espec&#237;fica, sino tambi&#233;n una epidemia mundial. Pacientes con IC tienen sus vidas perjudicadas por la enfermedad, e incluso el tratamiento optimizado parece tener diferentes impactos en su CDV. Su manejo implica un equipo multiprofesional que necesita cuidar la condici&#243;n cl&#237;nica del paciente, h&#225;bitos nutricionales, control del peso, cuidados no-farmacol&#243;gicos (ejercicio, educaci&#243;n, etc.)<sup>3</sup> Al tener en cuenta esos puntos, la literatura evidencia un espacio vac&#237;o significante entre lo que los profesionales de salud y los pacientes consideran como objetivos importantes<sup>5</sup>, sobretodo cuando aspectos simult&#225;neos de la enfermedad est&#225;n involucrados. As&#237;, m&#225;s estudios son necesarios para entender las relaciones entre la patolog&#237;a de la IC y los s&#237;ntomas y efectos de la IC en la CDV de los pacientes<sup>6</sup>. La comunidad cient&#237;fica hizo muchos esfuerzos para relacionar aspectos subjetivos y objetivos de la IC<sup>5,7</sup>. Esas consideraciones pueden ayudar a los profesionales de la salud a planificar estrategias para tratar esa disfunci&#243;n, no solamente con enfoque en los fines objetivos, sino tambi&#233;n en las expectativas de los pacientes. </p>
      <p>El presente estudio se desarroll&#243; para investigar la relaci&#243;n de los aspectos m&#225;s com&#250;nmente evaluados de la IC y la CDV de esos pacientes y como esos aspectos se comportan cuando se analizan ante otros.</p>
      <p>
        <bold>Pacientes y m&#233;todos </bold>
      </p>
      <p>
        <bold>Poblaci&#243;n</bold>
      </p>
      <p>Se reclutaron a 137 pacientes ambulatorios con IC (clase funcional I-III), usuarios del Sistema P&#250;blico de Salud Brasile&#241;o (SUS). De ese total, se consideraron a 101 en el an&#225;lisis final, ya que &#233;stos retornaron los informes completamente rellenados. </p>
      <p>Los criterios de inclusi&#243;n fueron: los pacientes deben estar estables y tener un diagn&#243;stico cl&#237;nico de IC llevado a cabo por experto asociado con FE <underline>&lt;</underline> 45% en la ecocardiograf&#237;a (dentro de 2 meses), sin infarto de miocardio reciente, as&#237; como angina inestable, accidente cerebrovascular, procedimiento de revascularizaci&#243;n coronaria por al menos 3 meses antes del inicio del estudio o uso de marcapaso. Pacientes con caquexia o dificultades en el desempe&#241;o de cualquier de esas pruebas no se incluyeron en el estudio.</p>
      <p>Se evaluaron los datos de caracterizaci&#243;n basados en informes cient&#237;ficos y pr&#225;ctica cl&#237;nica, que toman en consideraci&#243;n el manejo de la IC tales como g&#233;nero, etnia, &#237;ndice de masa corporal (IMC), presi&#243;n arterial promedio de reposo (PAPR), tiempo de diagn&#243;stico (TD) (desde hace 2 a&#241;os o m&#225;s de 2 anos), Clasificaci&#243;n Funcional seg&#250;n la New York Heart Association (CF-NYHA), Escala de Actividad Espec&#237;fica (EAE) de Goldman<sup>8</sup> para medir la capacidad funcional, comorbidades relacionadas a la edad (&#205;ndice de Charlson)<sup>9</sup> y el escore de riesgo de Framingham (ER) de acuerdo con las directrices de la Sociedad Brasile&#241;a de Cardiolog&#237;a<sup>10,11</sup>. </p>
      <p>
        <bold>Pruebas de funci&#243;n pulmonar</bold>
      </p>
      <p>Una prueba espirom&#233;trica fue realizada siguiendo la normativa de la Sociedad Tor&#225;cica Americana y la Sociedad Respiratoria Europ&#233;ia<sup>12</sup> (Espir&#243;metro Pony Graphics, Cosmed, Italia). Se obtuvieron datos como Capacidad Vital Forzada (CVF), Volumen Espiratorio Forzado en el 1<sup>er</sup> Segundo (FEV<sub>1</sub>), Raz&#243;n FEV<sub>1</sub>/FVC% y Ventilaci&#243;n Voluntaria M&#225;xima (VVM). Todos los valores se expresaron en porcentajes del total previsto para la poblaci&#243;n brasile&#241;a<sup>13</sup>.</p>
      <p>
        <bold>Composici&#243;n corporal </bold>
      </p>
      <p>El porcentaje de grasa corporal (Grasa%), masa libre de gras (MLG) y agua corporal total (ACT) se calcularon por impedancia bioel&#233;ctrica (BF 907, Maltron International, Reino Unido). La resistencia se midi&#243; en la posici&#243;n supina en el lado derecho como descrito por Lukaski et al.<sup>14</sup>.</p>
      <p>
        <bold>Calidad de Vida</bold>
      </p>
      <p>La CDV se midi&#243; con la versi&#243;n brasile&#241;a del cuestionario de Minnesota (Minnesota Living with Heart Failure Questionnaire), una medida enfermedad-espec&#237;fica que eval&#250;a las percepciones de los pacientes sobre la influencia de la IC en los aspectos f&#237;sicos, socioecon&#243;micos y psicol&#243;gicos de la vida<sup>15</sup>. Otra importante consideraci&#243;n sobre ese instrumento es su amplio formato, de f&#225;cil aplicaci&#243;n y el hecho de haber sido validado para la poblaci&#243;n brasile&#241;a<sup>16</sup>. Los participantes respondieron los 21 &#237;tems usando una escala de respuesta de seis puntos (0-5). El resumen del score total (score global) puede variar de 0 a 105; un score m&#225;s bajo refleja mejor CDV. Los scores en las 3 subescalas (dimensiones) reflejan dificultades f&#237;sicas (cuestiones n<sup>o. </sup>2, 3, 4, 5, 6, 7, 12 y 13), emocionales (cuestiones n<sup>o. </sup>17, 18, 19, 20 y 21) y los otros &#237;tems est&#225;n relacionados a consideraciones financieras, efectos colaterales de medicamentos y estilo de vida (dimensiones generales). Ese instrumento tambi&#233;n es adecuado para pacientes adultos mayores<sup>17</sup>.</p>
      <p>El Comit&#233; de &#201;tica de la Universidad Cat&#243;lica de Paran&#225; aprob&#243; este estudio, as&#237; como todos los pacientes firmaron el consentimiento informado para su participaci&#243;n. </p>
      <p>
        <bold>An&#225;lisis estad&#237;stico </bold>
      </p>
      <p>Se calcul&#243; la estad&#237;stica descriptiva para caracterizar la muestra a trav&#233;s de promedios &#177; desviaciones est&#225;ndar (<xref ref-type="table" rid="tab1-body2">Tabla 1</xref>). La correlaci&#243;n bivariada se hizo para un primer an&#225;lisis de la m&#225;s importante asociaci&#243;n entre los scores de CDV (dimensi&#243;n f&#237;sica, emocional y general y score global) y variables continuas. Al tener en cuenta la correlaci&#243;n bivariada y la experiencia cl&#237;nica, el an&#225;lisis de regresi&#243;n m&#250;ltiple se llev&#243; a cabo, y se eligieron como variables explicativas G&#201;NERO, ETNIA, CF-NYHA, FE, DDVI, DSVI, CHARLSON, CVF%PREV, FEV<sub>1</sub>%PRE, VVM%PREV, ER y EAE. La colinearidad entre las variables de la funci&#243;n pulmonar, particularmente en la CVF y FEV<sub>1</sub>, se conocen en situaci&#243;n normal, aunque estudios de pacientes con IC han evidenciado conclusiones variadas sobre ellas<sup>18</sup>, variando de valores normales las alteraciones restrictivas, la alteraci&#243;n restrictiva y obstructiva combinada<sup>18-20</sup>, y por tanto, se consideraron simult&#225;neamente como un modelo multivariado. Acto seguido, la regresi&#243;n backward stepwise para cada dimensi&#243;n se realiz&#243; a fin de establecer las variables m&#225;s influyentes para esa muestra. Todas las regresiones se llevaron a cabo y siguieron desde un an&#225;lisis de varianza para probar el poder de previsi&#243;n de la variable dependiente. Un valor de p &lt; 0,05 se consider&#243; como significante en comparaciones y correlaciones. G&#233;nero (Femenino=0 y Masculino=1), etnia (Caucasiano=0 y no-Caucasiano=1), TD (0-2 a&#241;os=0 y 2+ a&#241;os=1), clase funcional (Clase I = 0 y Clase II / III= 1) se consideraron como mudas ("dummy"), para volver la regresi&#243;n m&#250;ltiple posible. </p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Resultados </bold>
      </p>
      <p>De los 101 pacientes elegidos para ese an&#225;lisis, el 74% eran del sexo masculino (n=76) y el 26%, del femenino. La caracterizaci&#243;n de la muestra est&#225; detallada en la <xref ref-type="table" rid="tab1-body2">Tabla 1</xref>. </p>
      <p>
        <bold>Diferencias en la CDV en variables categ&#243;ricas</bold>
      </p>
      <p>No se encontr&#243; ninguna diferencia en la CDV con relaci&#243;n al g&#233;nero en todos los scores en las dimensiones, as&#237; como en el score general. Pacientes no-Caucasianos (n=39) parecen tener una CDV m&#225;s afectada en el score Global (42,54&#177;20,47), cuando comparados a los Caucasianos (n=62) (34,34&#177;16,38) para p=0,02863. Ellos tambi&#233;n presentaron un score mayor en la dimensi&#243;n General: no-Caucasianos (10,12&#177;6,2) <italic>versus</italic> Caucasianos (7,0&#177;5,3), p=0,008. Las otras dimensiones no presentaron diferencias significantes. Con relaci&#243;n al TD, la muestra se dividi&#243; en dos grupos (un grupo de 0 a 2 a&#241;os y un grupo con 2+ a&#241;os). Diferencias significantes se observaron solamente en la dimensi&#243;n Emocional, donde el grupo 2+ a&#241;os presentaba peores valores de score (16,07&#177;5) cuando comparado al grupo 0 a 2 a&#241;os (13,2&#177;8,2). Eso revela una disminuci&#243;n en los aspectos psicol&#243;gicos de pacientes con IC. En la <xref ref-type="table" rid="es_a15tab02-body2">Tabla 2</xref>, la prueba de Kruskall Wallys present&#243; diferencias significantes en la CDV seg&#250;n la CF (NYHA). El test <italic>post-hoc</italic> de Tukey evidenci&#243; que las Clases II e III no presentaban diferencias entre ellas (p=ns), aunque la Clase I tiene mejores scores en todas las dimensiones.</p>
      <p content-type="asset">
        <table-wrap id="es_a15tab02-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt02-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>An&#225;lisis de regresi&#243;n m&#250;ltiple</bold>
      </p>
      <p>A fin de diferenciar variables importantes que tienen una correlaci&#243;n con la CDV, inicialmente se hizo una prueba bivariada con cada variable continua y los scores del cuestionario de Minnesota. Esos resultados de correlaci&#243;n &#174; est&#225;n presentados en la <xref ref-type="table" rid="es_a15tab03-body2">Tabla 3</xref>. </p>
      <p content-type="asset">
        <table-wrap id="es_a15tab03-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt03-es.jpg"/></table-wrap>
      </p>
      <p>Los par&#225;metros ecocardiogr&#225;ficos, espirom&#233;tricos y de comorbilidades presentaron &#237;ndices de correlaci&#243;n significantes y repetidos en la mayor&#237;a de las dimensiones de la CDV. En un caso aislado, la dimensi&#243;n emocional present&#243; una correlaci&#243;n significante con edad y EAE, revelando un peor estado emocional de acuerdo con el envejecimiento y la disminuci&#243;n de la capacidad de ejercicio. Tras la identificaci&#243;n de esas importantes correlaciones bivariadas, se realiz&#243; el an&#225;lisis de regresi&#243;n m&#250;ltiple, excluyendo aquellas que no eran significantes. La literatura cient&#237;fica explica la importancia de la uni&#243;n entre el criterio de significancia estad&#237;stica y pr&#225;ctica<sup>21</sup>, as&#237; que se decidi&#243; a&#241;adir algunas variables que no fueran significantes en un an&#225;lisis univariado de esa muestra en el modelo multivariado, respectando la experiencia cl&#237;nica, como el ERF y la EAE. Tras diversas pruebas de regresi&#243;n, las variables comunes seleccionadas para los an&#225;lisis multivariados fueron: G&#201;NERO, ETNIA, CF-NYHA, FE, DDVI, DSVI, CHARLSON, CVF, FEV<sub>1</sub>, VVM, ERF Y EAE. Todas las variables se correlacionaron simult&#225;neamente a las dimensiones del cuestionario de Minnesota, en este caso considerado una variable dependiente. La <xref ref-type="table" rid="es_a15tab04-body2">Tabla 4</xref> presenta los niveles de significancia (p) de acuerdo con el nivel de correlaci&#243;n m&#250;ltiple (R y R<sup>2</sup>) de cada variable elegida. Niveles de p no significantes se indicaron por <italic>"ns</italic>".</p>
      <p content-type="asset">
        <table-wrap id="es_a15tab04-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt04-es.jpg"/></table-wrap>
      </p>
      <p>Variables categ&#243;ricas se consideraron como mudas como se explic&#243; anteriormente en m&#233;todos. A fin de verificar la necesidad de eliminar cualquier observaci&#243;n de valor discrepante, se efectu&#243; un an&#225;lisis de residuos y todos los casos se distribuyeron en &#177; 3,5 residuos estandarizados, de forma que no fue necesario excluir ning&#250;n dato. Finalmente, un an&#225;lisis de regresi&#243;n backward stepwise se realiz&#243; para identificar la variable m&#225;s influyente que contribuye al modelo multivariable. La <xref ref-type="table" rid="es_a15tab05-body2">Tabla 5</xref> revela los resultados del an&#225;lisis de regresi&#243;n backward stepwise de las dimensiones del cuestionario de Minnesota. </p>
      <p content-type="asset">
        <table-wrap id="es_a15tab05-body2">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt05-es.jpg"/></table-wrap>
      </p>
      <p>Bajo cada dimensi&#243;n es posible visualizar los valores de R y R<sup>2</sup>, donde R representa la correlaci&#243;n de las variables (dependiente <italic>versus</italic> independiente) y R<sup>2</sup> representa un coeficiente de regresi&#243;n en un nivel espec&#237;fico de significancia para un tama&#241;o de muestra espec&#237;fico. En ese estudio, los hallazgos m&#225;s importantes estaban relacionados con los scores globales del cuestionario de Minnesota, en el que 7 variables independientes pod&#237;an explicar de forma consistente el 60% de los resultados (g&#233;nero, etnia, DSVI, ERF, CVF, FEV<sub>1</sub>, VVM). Las otras dimensiones presentaron asociaciones significantes m&#225;s d&#233;biles.</p>
      <p>Un an&#225;lisis de varianza tras el modelo inicial multivariado y luego de la regresi&#243;n backward stepwise revel&#243; que las variables independientes pod&#237;an explicar los scores de las dimensiones del cuestionario de Minnesota (p&lt;0,05). Tambi&#233;n realizamos la Prueba F para cada regresi&#243;n, con la intenci&#243;n de probar la significancia de R, lo que es el mismo que probar la significancia de R<sup>2 </sup>. Todos los an&#225;lisis evidenciaron valores significantes para R y R<sup>2</sup>. Espec&#237;ficamente para scores Globales, se utiliza la regresi&#243;n stepwise en la fase exploratoria de la investigaci&#243;n o con prop&#243;sito de pura predicci&#243;n. Esta relaci&#243;n est&#225; detallada en forma de gr&#225;fico en la <xref ref-type="fig" rid="fig1-body2">Figura 1</xref>. </p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gf01-es.jpg"/></fig>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La IC es una disfunci&#243;n multifactorial que disminuye el estado funcional. Ella requiere hospitalizaciones frecuentes y afecta la expectativa de vida del paciente. Casi 5 millones de personas viven con IC, y 550 mil nuevos casos son diagnosticados cada a&#241;o<sup>22</sup>. Espec&#237;ficamente en el Brasil, la enfermedad resulta en altos gastos para el paciente y para el sistema p&#250;blico de salud<sup>4,23</sup>. Al analizar las causas cl&#237;nicas responsables del alto n&#250;mero de hospitalizaciones en el 2002, bajo la responsabilidad del Sistema &#218;nico de Salud (SUS) brasile&#241;o, la IC qued&#243; en tercer lugar (372.604), tras neumon&#237;a (794.260) y asma (376.447)<sup>4</sup>. Estrategias para mejorar resultados enfocando no solamente desenlaces objetivos y fisiol&#243;gicos son primordiales para su manejo, objetivando resultados m&#225;s amplios<sup>24,25</sup>. La CDV en la IC es todav&#237;a un complejo objeto de investigaci&#243;n e incluso en el presente estudio, y no est&#225; a&#250;n bien establecido. Muchos aspectos pueden influir en su evaluaci&#243;n (aspectos biopsicosociales), y estos puntos estimulan su investigaci&#243;n. El presente estudio sugiere que la CDV en la IC se debe analizar a trav&#233;s de una visi&#243;n multiangular. Eso puede observarse en las asociaciones de los scores Globales, donde siete variables distintas independientes pueden explicar aproximadamente el 60% de los resultados de CDV de la muestra cuando analizadas simult&#225;neamente. La etnia es uno de los factores a tener en cuenta en nuestro estudio. Pacientes no-caucasianos presentan una CDV peor cuando comparados a los caucasianos. La literatura explica que hay diferencias entre las etnias en la prevalencia, la etiolog&#237;a y los desenlaces de la IC<sup>26</sup>. Como mencionado por Taylor et al.<sup>27</sup>, cuando comparados a los caucasianos, los afro-americanos presentan tasas acentuadamente m&#225;s altas de diagn&#243;stico de IC, tienen mayor probabilidad de hipertensi&#243;n que enfermedad arterial coronaria, mueren m&#225;s r&#225;pidamente y son hospitalizados m&#225;s frecuentemente debido a la IC. Aun con los avances de la terapia cardiaca en los Estados Unidos, ellos no se benefician de forma equivalente. Por ejemplo, pacientes afrodescendientes no responden tan bien a la acci&#243;n del inhibidor de enzima conversora de la angiotensina (IECA)<sup>28</sup>. No hay estudios con la poblaci&#243;n afrodescendiente brasile&#241;a, pero el mismo mecanismo parece estar implicado. Adicionalmente, diferencias &#233;tnicas pueden estar relacionadas no solamente al manejo de la IC o su fisiopatolog&#237;a, sino concomitantemente a los sistemas de salud y social brasile&#241;os, donde el negro tiene menos condiciones de acceso para prevenci&#243;n y tratamiento de diversas enfermedades<sup>29,30</sup>. La Clasificaci&#243;n Funcional de la NYHA es un esquema de clasificaci&#243;n general derivada del proveedor ampliamente utilizado para categorizar pacientes en cuanto a los s&#237;ntomas asociados con las actividades diarias. Nuestro estudio, as&#237; como otros, evidenci&#243; diferencias significantes en las clases funcionales de la NYHA cuando se compar&#243; la CDV entre ellas. Bennet et al.<sup>31</sup> encontraron diferencias en la CDV, a excepci&#243;n de las clases III e IV. El presente estudio no tuvo en cuenta la clase IV debido a las dificultades t&#233;cnicas en la realizaci&#243;n de algunas pruebas, tales como espirometr&#237;a, que causa extrema disnea en pacientes de clase IV. Se observ&#243; que as&#237; como en las clases NYHA, pacientes de clase I presentaban menos impacto evidente en su CDV. El an&#225;lisis multivariado mostr&#243; que la Clasificaci&#243;n Funcional de la NYHA es una variable de influencia importante en la CDV de los pacientes, espec&#237;ficamente en los scores Global y Dimensi&#243;n Emocional. La Clasificaci&#243;n Funcional de la NYHA present&#243; una relaci&#243;n significante con vitalidad y salud mental en un estudio usando SF-36<sup>5</sup>, al sugerir que las Clases NYHA deben evaluarse teniendo en cuenta no solamente los aspectos f&#237;sicos, sino tambi&#233;n los subjetivos. Las correlaciones bivariadas demostraron una asociaci&#243;n baja, aunque significante, entre los par&#225;metros ecocardiogr&#225;ficos tales como FE, DDVI y DSVI, evidenciando que la capacidad de gasto cardiaco deficiente y di&#225;metro sist&#243;lico y diast&#243;lico aumentado del ventr&#237;culo izquierdo causado por sobrecarga podr&#237;an perjudicar la CDV. Myers et al.<sup>32</sup>, usando otro instrumento de evaluaci&#243;n de CDV revelaron una d&#233;bil, aunque significante correlaci&#243;n entre FE y CDV<sup>32</sup>. Mitani et al.<sup>5</sup>, usando un instrumento gen&#233;rico de evaluaci&#243;n (SF-36)<sup>33</sup>, no observaron ninguna asociaci&#243;n entre esos par&#225;metros. En un estudio importante para esa &#225;rea, Grigioni et al.<sup>24</sup>, al utilizar el cuestionario de Minnesota, tambi&#233;n no encontraron ninguna asociaci&#243;n entre el ecocardiograma y los par&#225;metros de CDV. Sin embargo, ellos tuvieron en cuenta las clases NYHA I a IV. Es interesante el hecho de que, cuando realizamos el an&#225;lisis multivariado, s&#243;lo el DSVI permaneci&#243; como un factor de influencia general en la CDV. Estudios adicionales ser&#237;an importantes para aclarar esos puntos. </p>
      <p>El &#205;ndice de Comorbilidad de Chalson<sup>9,34</sup> revela un pron&#243;stico basado en la edad y condiciones de comorbilidad; con cada nivel aumentado del &#237;ndice de comorbilidad, la mortalidad acumulativa atribuible a la enfermedad com&#243;rbida aumenta de forma gradual. En nuestro estudio, las comorbilidades tuvieron una correlaci&#243;n bivariada significante con la CDV y aunque el modelo multivariado no ha evidenciado significancia estad&#237;stica, hemos podido observar una tendencia (p=0,082518). La comorbilidad en pacientes con IC puede contribuir a las dificultades diagn&#243;sticas en pacientes mayores<sup>35</sup> y est&#225; directamente asociada al pron&#243;stico cuando se tiene en cuenta la mortalidad<sup>36</sup>. Hace falta estudios espec&#237;ficos que relacionen la CDV en la IC y las comorbilidades. El ERF se revel&#243; un importante aspecto a tener en cuenta al evaluar la CDV en la IC, ya que sus m&#250;ltiples scores consideran no solamente el impacto de las variables espec&#237;ficas como edad, colesterol, presi&#243;n arterial y fumo, sino tambi&#233;n el sinergismo entre ellas<sup>11</sup>. Su presencia en el modelo backward stepwise evidenci&#243; la importancia de la experiencia cl&#237;nica en la evaluaci&#243;n de pacientes con IC. </p>
      <p>El presente estudio evidenci&#243; que la funci&#243;n pulmonar estaba disminuida y que eso ten&#237;a una relaci&#243;n importante con la CDV de los pacientes. La correlaci&#243;n bivariada evidenci&#243; que scores m&#225;s altos en el cuestionario de Minnesota presentaban resultados peores en la espirometria. La Capacidad Vital Forzada y FEV<sub>1</sub> disminuidos y raz&#243;n FEV<sub>1</sub>/CVF normal se observaron en la muestra y corroborado por Johnson et al.<sup>18</sup> y Forgiarini et al.<sup>19</sup>. Sin embargo, otros estudios no relacionaron disfunci&#243;n pulmonar y CDV en la IC. Otro aspecto importante a evidenciar es que, como m&#237;nimo, un par&#225;metro de funci&#243;n pulmonar estaba asociado a la CDV (dimensiones). Los valores respiratorios anormales podr&#237;an atribuirse a factores musculares<sup>19,37-39</sup>, lo que puede explicar los s&#237;ntomas de falta de aire y la reducci&#243;n en la capacidad de ejercicio adem&#225;s de la posici&#243;n del diafragma que est&#225; alterada en la IC y que provoca una desventaja mec&#225;nica en la eficacia respiratoria como resultado de una respuesta adaptativa a la alteraci&#243;n en la raz&#243;n cardiotor&#225;cica por el desplazamiento mec&#225;nico directo del diafragma debido al aumento del coraz&#243;n<sup>40</sup>.</p>
      <p>El hallazgo m&#225;s importante de ese estudio est&#225; relacionado a los efectos simult&#225;neos de las variables y de la CDV de los pacientes en los an&#225;lisis multivariado. Al contar con todas las correlaciones bivariadas relacionadas a las variables de la CDV sumadas a las variables basadas en experiencia pr&#225;ctica, se evidenci&#243; un R<sup>2</sup>= 0,64 y tras la aplicaci&#243;n del modelo backward stepwise, conseguimos un R<sup>2</sup>= 0,60. El modelo backward stepwise es un m&#233;todo de b&#250;squeda secuencial que empieza con todas las variables y elimina aquellas que son independientes una de cada vez, hasta que la eliminaci&#243;n de una resulte en una diferencia significante en R<sup>2</sup>. En nuestro caso, elegimos variables explicativas que prove&#237;an buenos predictores de CDV, tales como g&#233;nero, etnia, DSVI, ERF, CVF, FEV<sub>1</sub>, VVM (<xref ref-type="table" rid="es_a15tab04-body2">Tabla 4</xref>). </p>
      <p>Respecto a las limitaciones del estudio, se puede observar que las variables estudiadas todav&#237;a fallan en detectar alrededor del 40% de la variancia de la CDV y eso puede estar relacionado no solamente a las variables objetivas, sino a otros aspectos de la enfermedad que no pudieron encontrarse en el presente estudio. A&#250;n as&#237;, este estudio es el primer paso en la tentativa de correlacionar un aspecto tan importante y poco comprendido de la evaluaci&#243;n de la IC y nos parece que estudios futuros con muestras mayores adem&#225;s de la inclusi&#243;n de otras variables independientes -como por ejemplo fumo, pr&#225;ctica de ejercicios y ocio, apoyo psicol&#243;gico y otras- pueden explicar las grandes variaciones en la CDV. </p>
      <p>En conclusi&#243;n, g&#233;nero, etnia, DSVI, ERF, CVF, FEV<sub>1</sub> y VVM se pueden considerar como predictores independientes de la CDV en pacientes con IC; juntas, ellos representan alrededor del 60% de la varianza de la CDV. Este estudio evidencia que la CDV est&#225; afectada en pacientes con IC y que es importante tenerla en cuenta en el manejo de la enfermedad. Otros aspectos adem&#225;s de los objetivos tambi&#233;n son fundamentales en la vida diaria del paciente con IC. El presente estudio aconseja a los profesionales de la salud a no enfatizar solamente los resultados fisiol&#243;gicos, sino tambi&#233;n a tener en cuenta los aspectos hol&#237;sticos tales como influencias psicol&#243;gicas y funcionalidad, las que pueden afectar el estado general del paciente. </p>
      <p>
        <bold>Agradecimientos</bold>
      </p>
      <p>El estudio se condujo con el apoyo de la Universidad del Paran&#225; (Brasil) y el Programa de Doctorado en Ciencias de la Salud de la Universidad Cat&#243;lica de Paran&#225; (Brasil).</p>
      <p>Agradecemos al Prof. Dr. Roberto Pecoits Filho y a la Dr&#170;. Fabiane Nascimento por sus sugerencias &#250;tiles al pre proyecto del estudio. </p>
      <p>Los autores agradecen a la Prof&#170;. Marcia Olandoski por su ayuda con el an&#225;lisis estad&#237;stico. </p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El Programa de Capacitaci&#243;n Docente de la Universidad Paranaense - UNIPAR financi&#243; parte del presente estudio.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Jefferson J. Amaral dos Santos, por la Pontificia Universidad Cat&#243;lica de Paran&#225;.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Quality of life and clinical indicators in heart failure: a multivariate analysis</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: In Heart Failure (HF), special attention must be given not only to objective or isolated aspects, but also to the patient's health self-perceptions. Subjective aspects can help healthcare providers understand and better treat HF. OBJECTIVE: The objective of this study was to evaluate the simultaneous effects of clinical indicators of HF on the Quality-of-Life (QOL). METHODS: We investigated, through a multivariate analysis, the QOL of 101 Brazilian HF outpatients using the Minnesota Living with Heart Failure Questionnaire (including subscales) and its correlation to clinical and physiological variables such as age, ethnicity, gender, echocardiogram parameters, body mass index, mean blood pressure at rest, time since diagnosis, Functional Classification according to the NYHA, functional capacity by a Specific Activity Scale, comorbidities, Framingham Score of Cardiac Risk (CR), Lung Function Test (spirometry) and Body Composition. RESULTS: QOL showed significant univariate correlations to the echocardiogram: ejection fraction (p=0.0415), left ventricular diastolic diameter (LVDD) (p=0.004), left ventricular systolic diameter (LVSD) (p=0.0001); comorbidities (p=0.002) and Lung Function Test: Forced Vital Capacity (FVC) (p&lt;0.0001), Forced Expiratory Volume in the 1st second (FEV1) (p&lt;0.0001) and Maximal Voluntary Ventilation (MVV) (p=0.001). In the multivariate analysis, the backward stepwise protocol detected important simultaneous influent variables (r&#178;=0.60): gender (0.000178), ethnicity (p&lt;0.00001), LVSD (P&lt;0.00001), CR (p=0.000002), FVC (p=0.002027), FEV1 (p&lt;0.00001) and MVV (p=0.00001). CONCLUSION: Gender, ethnicity, LVSD, CR, FVC, FEV1 and MVV are independent predictors of HF patients' QOL. Simultaneously, they are responsible for about 60% of the QOL variance. Biopsychosocial aspects could contribute to patient and health professional expectations and treatment results.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart Failure</kwd>
        <kwd>Quality of Life</kwd>
        <kwd>Holistic Health</kwd>
        <kwd>Multivariate Analysis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <fig id="cima-body3"/>
      <p>Quality of life and clinical indicators in heart failure: a multivariate analysis</p>
      <p>
        <bold>Jefferson Jovelino Amaral dos Santos<sup>I</sup>; Jony Erwin Andreola Plewka<sup>II</sup>; Paulo Roberto Slud Brofman<sup>III</sup></bold>
      </p>
      <p><sup>I</sup>Universidade Paranaense (UNIPAR), Toledo, PR</p>
      <p><sup>II</sup>Instituto de Cardiologia de Toledo, Toledo, PR</p>
      <p><sup>III</sup>Programa de Doutorado em Ci&#234;ncias da Sa&#250;de (PUCPR), Curitiba, PR, Brasil </p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> In Heart Failure (HF), special attention must be given not only to objective or isolated aspects, but also to the patient's health self-perceptions. Subjective aspects can help healthcare providers understand and better treat HF. </p>
      <p><bold>OBJECTIVE:</bold> The objective of this study was to evaluate the simultaneous effects of clinical indicators of HF on the Quality-of-Life (QOL).</p>
      <p><bold>METHODS:</bold> We investigated, through a multivariate analysis, the QOL of 101 Brazilian HF outpatients using the Minnesota Living with Heart Failure Questionnaire (including subscales) and its correlation to clinical and physiological variables such as age, ethnicity, gender, echocardiogram parameters, body mass index, mean blood pressure at rest, time since diagnosis, Functional Classification according to the NYHA, functional capacity by a Specific Activity Scale, comorbidities, Framingham Score of Cardiac Risk (CR), Lung Function Test (spirometry) and Body Composition.</p>
      <p><bold>RESULTS:</bold> QOL showed significant univariate correlations to the echocardiogram: ejection fraction (p=0.0415), left ventricular diastolic diameter (LVDD) (p=0.004), left ventricular systolic diameter (LVSD) (p=0.0001); comorbidities (p=0.002) and Lung Function Test: Forced Vital Capacity (FVC) (p&lt;0.0001), Forced Expiratory Volume in the 1st second (FEV<sub>1</sub>) (p&lt;0.0001) and Maximal Voluntary Ventilation (MVV) (p=0.001). In the multivariate analysis, the backward stepwise protocol detected important simultaneous influent variables (r<sup>2</sup>=0.60): gender (0.000178), ethnicity (p&lt;0.00001), LVSD (P&lt;0.00001), CR (p=0.000002), FVC (p=0.002027), FEV<sub>1</sub> (p&lt;0.00001) and MVV (p=0.00001).</p>
      <p><bold>CONCLUSION:</bold> Gender, ethnicity, LVSD, CR, FVC, FEV<sub>1 </sub>and MVV are independent predictors of HF patients' QOL. Simultaneously, they are responsible for about 60% of the QOL variance. Biopsychosocial aspects could contribute to patient and health professional expectations and treatment results.</p>
      <p><bold>Key words:</bold> Heart Failure; Quality of Life; Holistic Health; Multivariate Analysis.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Assessing Quality of Life (QOL) has become indispensable when evaluating a patient in clinical practice. The World Health Organization defines QOL as "an individual's perception of their position in life, in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns"<sup>1</sup>. </p>
      <p>Heart Failure (HF) is a clinical syndrome resulting from a structural or functional cardiac disorder that impairs the capacity of the ventricle to fill with or eject enough blood according to the body demands, or when it does it with increased filling pressures. Its prevalence is estimated approximately as being 2.3% in general population<sup>2</sup> and 0.4% to 2.0% in the European population<sup>3</sup>; Approximately 5 million people in the United States have HF and it results in about 300,000 deaths each year. In Brazil, the largest country in South America, HF is the third cause of all hospitalizations<sup>4</sup>. HF is not just a specific population disease, but also a world epidemic.</p>
      <p>Patients with HF have their lives impaired by the disease, and even with optimal treatment, the disease seems to have different degrees of impact on their QOL. Its management involves a multi-professional staff that must take care of the patient's clinical condition, dietary habits, weight management and non-pharmacological care (exercise, education, etc)<sup>3</sup>.</p>
      <p>Considering these points, the literature shows a significant gap between what health professionals consider to be important goals and what patients do<sup>5</sup>, especially when simultaneous aspects of the disease are involved. Therefore, more studies are needed to understand the associations between the pathology of HF and symptoms and the effects of HF on patients' QOL<sup>6</sup>. Many efforts have been made by the scientific community to correlate the subjective and objective aspects of HF<sup>5,7</sup>. These considerations could help health professionals to outline strategies to manage this dysfunction, not only focused on objective goals, but also on the patients' expectations.</p>
      <p>The present study was developed to investigate the association between the most commonly assessed clinical aspects of HF and the QOL of these patients, and how these aspects behave when they are analyzed in the presence of others. </p>
      <p>
        <bold>Subjects and Methods</bold>
      </p>
      <p>
        <bold>Population</bold>
      </p>
      <p>One hundred-thirty seven ambulatory HF patients (functional class I-III), users of the Brazilian Public Health Care System were recruited, although only 101 were considered in the final analysis because the fully completed reports were returned.</p>
      <p>The inclusion criteria were: stable patients with a clinical diagnosis of HF made by an experienced specialist associated with an ejection fraction <underline>&lt;</underline>45% at the echocardiography (performed in the last 2 months), with no recent myocardial infarction, unstable angina, stroke, coronary revascularization procedure for at least 3 months before enrollment or pacemaker use. Patients with cachexia or difficulties to perform any of the tests were not included in the study.</p>
      <p>Characterization data based on scientific reports and clinical practice, which take into account HF management such as gender, ethnicity, body mass index (BMI), mean blood pressure at rest (MBPR), Time since Diagnosis (TD) (up to 2 years or more than two years), Functional Classification according to the New York Heart Association (NYHA), Goldman's Specific Activities Scale (SAS)<sup>8</sup> for measuring functional capacity, comorbidities related to age (Charlson's Index)<sup>9</sup> and Framingham Score of Cardiac Risk (CR) according to the Brazilian Cardiology Society Guidelines<sup>10,11</sup> were assessed.</p>
      <p>
        <bold>Lung Function Tests</bold>
      </p>
      <p>A spirometric test was performed according to the American Thoracic Society and European Respiratory Society Standardization<sup>12</sup> (Pony Graphics Spirometer, Cosmed, Italy). Data such as Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV<sub>1</sub>), FEV<sub>1</sub>/FVC% ratio and Maximal Voluntary Ventilation (MVV) were recorded. All values were expressed as percentages of the total values predicted for the Brazilian population<sup>13</sup>. </p>
      <p>
        <bold>Body Composition </bold>
      </p>
      <p>Fat percent (Fat%), Fat-free mass (FFM) and Total Body Water (TBW) were measured by bioelectrical impedance (BF 907, Maltron International, UK). Resistance was measured in the supine position on the right side as described by Lukaski et al<sup>14</sup>.</p>
      <p>
        <bold>Quality of Life</bold>
      </p>
      <p>QOL was measured using the Brazilian version of the Minnesota Living with Heart Failure Questionnaire (MLHF), a disease-specific measure that assesses patients' perceptions of the influence of HF on physical, socioeconomic, and psychological aspects of life<sup>15</sup>. Other important considerations about this instrument is the fact that it is a comprehensive, easy to apply tool and it has been validated for the Brazilian population<sup>16</sup>. Participants answered the 21 items using a 6-point response scale (0-5). The total summary score (Global Score) can vary from 0 to 105; a lower score reflects better QOL. Three subscale scores (dimensions) reflect physical (questions<sup>. </sup>2, 3, 4, 5, 6, 7, 12 and 13) and emotional (questions<sup>. </sup>17, 18, 19, 20 and 21) impairment and the other items are related to financial, medication side-effects, and lifestyle considerations (overall dimensions). This instrument is also suitable for older patients<sup>17</sup>.</p>
      <p>This study was approved by the Catholic University of Paran&#225; Ethics Committee and all patients gave their formal consent for participation.</p>
      <p>
        <bold>Statistical Analysis</bold>
      </p>
      <p>Descriptive statistics were computed to characterize the sample through means &#177; standard deviations (<xref ref-type="table" rid="tab1-body3">Table 1</xref>). A bivariate correlation was performed for a first analysis of the most important association between QOL scores (physical, emotional, overall dimensions and global score) and continuous variables. Considering the bivariate correlation and clinical experience, the multiple regression analysis was performed by choosing as explanatory variables GENDER, ETHNICITY, NYHA, EF, LVDD, LVSD, CHARLSON, FVC%PRED, FEV1%PRE, MVV%PRED, CR and SAS. Colinearity among pulmonary function variables, particularly in FVC and FEV1, are known in normal situation, although studies have shown varied results in HF patients<sup>18</sup>, ranging from normal values, to restrictive alterations, to combined restrictive and obstructive alterations<sup>18-20</sup>. Therefore, they were considered simultaneously in a multivariate model. In sequence, the backward stepwise regression for each dimension was performed in order to establish the most influential variables for this sample. All regressions were performed followed by an analysis of variance to test the power of dependent variable prediction. A p &lt; 0.05 was considered significant in comparisons and correlations.</p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt01-en.jpg"/></table-wrap>
      <p>Gender (Female=0 and Male=1), ethnicity (White=0 and non-white=1), TD (0-2 years=0 and 2+ years=1), functional class (Class I = 0 and Class II / III= 1) were considered dummy variables to make the multiple regression possible. </p>
      <p>
        <bold>Results </bold>
      </p>
      <p>Of the 101 patients considered for this analysis, 74% were males (n=76) and 26% were females. Characterization of the sample is provided in <xref ref-type="table" rid="tab1-body3">Table 1</xref>.</p>
      <p>
        <bold>QOL Differences in categorical variables</bold>
      </p>
      <p>No differences were found in the QOL in relation to gender in all dimension scores as well as in the global score.</p>
      <p>Non-Caucasian (n=39) patients seem to present a more affected QOL in Global Score (42.54&#177;20.47) than Caucasian ones (n=62) (34.34&#177;16.38) for p=0.02863. They also presented higher scores in the Overall dimension: non-Caucasian (10.12&#177;6.2) <italic>versus</italic> Caucasian (7.0&#177;5.3), p=0.008. The other dimensions did not show significant differences.</p>
      <p>In relation to TD, the sample was divided in two groups (a 0 to 2 year group and a 2+ year group). Significant differences were found only in the Emotional dimension, where the 2+ year group had worse score values (16.07&#177;5) when compared to the 0 to 2 year group (13.2&#177;8.2). This shows a decrease in the psychological aspects of HF patients. In <xref ref-type="table" rid="en_a15tab02-body3">Table 2</xref>, the Kruskall Wally's Test showed significant differences in QOL according to functional class (NYHA). Post-hoc Tukey's test showed that there was no difference between patients from Class II and III (p=ns), whereas Class I patients had better scores in all dimensions.</p>
      <p content-type="asset">
        <table-wrap id="en_a15tab02-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt02-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Multiple regression analysis.</bold>
      </p>
      <p>In order to identify important variables that presented a correlation with QOL, a bivariate test was initially performed with each continuous variable and the MLHF scores. </p>
      <p>Those correlation results (r) are shown in <xref ref-type="table" rid="en_a15tab03-body3">Table 3</xref>.</p>
      <p content-type="asset">
        <table-wrap id="en_a15tab03-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt03-en.jpg"/></table-wrap>
      </p>
      <p>Echocardiographic, spirometric and comorbidity parameters showed significant and repeated correlation indexes in most of QOL dimensions. In an isolate case, the emotional dimension had a significant correlation with age and SAS, showing a worse emotional status according to aging and the decrease of exercise capability. After identification of those important bivariate correlations, we proceeded with the multiple regression analysis, excluding those what were not significant. The scientific literature explains the importance of the union between the criterion of statistical and practical significance<sup>21</sup>, so it has been decided to add some variables that were not significant in the univariate analysis of this sample to the multivariate design, respecting clinical experience, such as CR and the SAS. After several regression tests, the common selected variables for multivariate analyses were: GENDER, ETHNICITY, NYHA, EF, LVDD, LVSD, CHARLSON, FVC, FEV1, MVV, CR and SAS. All of those variables were simultaneously correlated to the MLHF dimensions, in this case considered as a dependent variable.</p>
      <p><xref ref-type="table" rid="en_a15tab04-body3">Table 4</xref> shows the significance levels (p) according to multiple correlation levels (r and r<sup>2</sup>) of each chosen variable. Non-significant (p) levels are indicated by <italic>"ns</italic>".</p>
      <p content-type="asset">
        <table-wrap id="en_a15tab04-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt04-en.jpg"/></table-wrap>
      </p>
      <p>Categorical variables were considered as dummy variables as explained in Methods. In order to verify the necessity of deleting any outlier observation, an analysis of residuals was performed and all cases were distributed in &#177;3.5 standards residuals so, there was no need for data exclusion.</p>
      <p>Finally, a backward stepwise regression was carried out in order to identify the most influent variables that contributed with the multivariable model. <xref ref-type="table" rid="en_a15tab05-body3">Table 5</xref> shows the results of the backward stepwise regression analysis of the MLHF dimensions.</p>
      <p content-type="asset">
        <table-wrap id="en_a15tab05-body3">
          <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gt05-en.jpg"/></table-wrap>
      </p>
      <p>It is possible to visualize R and R<sup>2</sup> values under each of the dimensions where R represents the correlation of variables (dependent <italic>versus</italic> independent) and R<sup>2</sup> represents a regression coefficient at a specific significance level for a specific sample size. In this study, the most important findings were associated with the MLHF Global Scores, where seven independent variables could consistently explain 60% of the results (gender, ethnicity, LVSD, CR, FVC, FEV<sub>1</sub>, MVV). The other dimensions had weaker significant associations.</p>
      <p>An analysis of variance after the initial multivariate model and after the backward stepwise method was employed showed that the independent variables could explain the MLHF dimension scores (p&lt;0.05). We also performed the F-test for each regression in order to test the significance of R, which is the same as testing the significance of R<sup>2. </sup> All analyses showed significant values for R and R<sup>2</sup>.</p>
      <p>Specifically for Global Scores, the stepwise regression method is used in the exploratory phase of research or for purposes of pure prediction; we demonstrate this association in <xref ref-type="fig" rid="fig1-body3">Figure 1</xref>.</p>
      <fig id="fig1-body3">
        <graphic xlink:href="1678-4170-abc-93-02-0159-00015-gf01-en.jpg"/></fig>
      <p>
        <bold>Discussion </bold>
      </p>
      <p>HF is a multifactorial dysfunction that decreases functional status; it requires frequent hospitalizations and affects patients' life expectancy. Nearly 5 million Americans are currently living with HF, and 550,000 new cases are diagnosed each year<sup>22</sup>. Specifically in Brazil, it results in a large amount of expenses for the patients and the public health system<sup>4,23</sup>. When analyzing the clinical causes that have resulted in the highest numbers of hospital admissions in 2002, under the Brazilian Public health System responsibility, HF was ranked third (372,604), after pneumonia (794,260) and asthma (376,447)<sup>4</sup>. Strategies to improve outcomes that focus not only on objective and physiological outcomes are primordial for its management, aiming at wider results<sup>24,25</sup>.</p>
      <p>QOL in HF is still a complex object of study and it has not been well established to date. Many aspects can influence its assessment (biopsychosocial aspects), and these point stimulate its investigation.</p>
      <p>The present study suggests that QOL in HF has to be analyzed in a multiple-angle view. That was observed in Global Score associations, where seven distinct independent variables explained about 60% percent of the sample QOL results when analyzed simultaneously. </p>
      <p>Ethnicity is one of the factors to be considered in our study. Non-Caucasian patients have a poorer QOL when compared to Caucasian ones. Literature explains that there are differences among ethnicities regarding the prevalence, etiology, and outcomes of HF<sup>26</sup>. As cited by Taylor et al<sup>27</sup>, compared to Caucasians, African-Americans are diagnosed with HF at a markedly higher rate, are more likely to have hypertension than coronary artery disease, die more quickly, and are more often hospitalized due to HF. Even with the advances of cardiac therapy in the United States, they do not benefit equally; for instance, African-American patients do not respond as well as Caucasians to the angiotensin-converting enzyme inhibitor<sup>28</sup>. There have been no studies carried out with the African-Brazilian population, but the same mechanism seems to be involved. Moreover, ethnic differences might be related not only to HF management or physiopathology, but also to the Brazilian health and social systems, where African descendants have less access to prevention and treatment of several diseases<sup>29,30</sup>. </p>
      <p>The NYHA Functional Classification is a widely used general (4 categories), provider-derived classification scheme to categorize patients in terms of symptoms associated with daily activities.</p>
      <p>Our study, similarly to others, showed significant differences in NYHA functional classes when their QOL were compared. Bennet et al<sup>31</sup>, found differences in QOL except in classes III and IV. The present report did not take into consideration class IV because of the technical difficulties in the performance of some tests such as spirometry, which causes extreme dyspnea to class IV patients. It was observed that as in NYHA classes, class I patients have less evident impairment of their QOL. The multivariate analysis showed NYHA Functional Classification as an important influence variable in the patients' QOL, specifically in Global Scores and Emotional Dimension. NYHA Functional Classification showed a significant association with vitality and mental health in a study using SF-36<sup>5</sup>, suggesting that NYHA Classes must be assessed taking into consideration not only the physical aspects, but also the subjective ones. </p>
      <p>Bivariate correlations demonstrated weak but significant associations between echocardiogram parameters such as EF, LVDD and LVSD, showing that a poor output capacity and an enlarged systolic and diastolic diameter of the left ventricle caused by overload can impair QOL. Myers et al<sup>32</sup>, using another QOL instrument, demonstrated weak but significant correlations between EF and QOL<sup>32</sup>. Mitani et al<sup>5</sup>, using a generic instrument (SF-36)<sup>33</sup>, found no associations among these parameters. In an important study for this area, Grigioni et al<sup>24</sup>, using the MLHF questionnaire, also found no association between echocardiogram and QOL parameters; however, they considered NYHA classes I to IV. Interestingly, when we performed the multivariate analysis, only LVSD remained as an overall influential factor for QOL. Additional studies would be important to clarify these points.</p>
      <p>The Chalson Comorbidity Index<sup>9,34</sup> shows the prognosis based on age and comorbid conditions and with each increased level of the comorbidity index, the cumulative mortality attributable to comorbid diseases increases in a step-wise fashion. In our study, comorbidities had a significant bivariate correlation with QOL and although the multivariate model did not show statistically important significance, we could observe a tendency (p=0.082518) in it. Comorbidity in HF patients can contribute to diagnosis difficulties in older patients<sup>35</sup> and is directly associated with prognosis when considering mortality<sup>36</sup>. There is a scarcity of previous specific studies correlating QOL in HF with comorbidities.</p>
      <p>CR showed to be an important aspect to be considered when assessing QOL in HF, as its multiple score takes into consideration not only the impact of specific variables as age, cholesterol levels, blood pressure and smoking, but also their synergism<sup>11</sup>. Its presence in the backward stepwise model showed the importance of clinical experience when evaluating HF patients.</p>
      <p>This research showed that pulmonary function is impaired and had a significant association with the patients' QOL. The bivariate correlation showed that higher MLHF scores had worse results at the spirometry. Decreased FVC and FEV<sub>1</sub> and a normal FEV<sub>1</sub>/CVF were observed in the sample and this is corroborated by Johnson et al<sup>18</sup> and Forgiarini et al<sup>19</sup>; however, other studies did not correlate pulmonary dysfunction and QOL in HF. Another important aspect to consider is that at least one pulmonary function parameter was associated with QOL (dimensions). Abnormal respiratory values could be attributed to muscular factors<sup>19,37-39</sup>, which explains breathlessness and reduced exercise capacity beyond the diaphragm position; this is altered in HF, causing a mechanical disadvantage in respiratory efficacy as a result of an adaptive response to a change in the cardio-thoracic ratio by the direct mechanical displacement of the diaphragm due to an increase in heart size<sup>40</sup>.</p>
      <p>The most important finding of this work is related to the simultaneous effects of the variables and the patient's QOL in the multivariate analysis. Considering all bivariate correlations related to QOL variables plus practical experience-based variables, it was demonstrated that R<sup>2</sup>= 0.64 and after the backward stepwise method, R<sup>2</sup>= 0.60. The backward stepwise model is a sequential search method that starts with all variables and eliminating independents one at a time until the elimination of one makes a significant difference in R-squared. In our case, we selected explanatory variables that provided good predictors of QOL such as gender, ethnicity, LVSD, CR, FVC, FEV<sub>1</sub>, MVV (<xref ref-type="table" rid="en_a15tab04-body3">Table 4</xref>). </p>
      <p>The limitations of this study include the fact that the studied variables still failed in determining about forty percent of QOL variance and this could be related not only to the objective variables, but to other disease aspects that were not found in the present study; yet, this work is a first step in an attempt to correlate a very important and misunderstood aspect of HF assessment and we believe that further studies with larger sample sizes and the inclusion of other independent variables such as smoking exercise practice and leisure, psychological support and others might explain larger variations of QOL. </p>
      <p>In conclusion, gender, ethnicity, LVSD, CR. FVC, FEV<sub>1 </sub>and MVV can be considered independent predictors of HF patients' QOL; together, they represent about 60% of the QOL variance. This study showed that QOL is affected in HF patients and it is important to be considered in the disease management. Other aspects in addition to the objective ones are also fundamental in the HF patient daily living. This reminds health care professionals to emphasize not only the physiological results, but also to be aware of holistic aspects such as cultural and social life, psychological influences and functionality that could affect the patient's global status. </p>
      <p>
        <bold>Acknowledgements </bold>
      </p>
      <p>The study was carried out with the support of University of Paran&#225; (Brazil) and Health Sciences Doctoral Program of the Catholic University of Paran&#225; (Brazil).</p>
      <p>Special thanks to Prof. Dr. Roberto Pecoits Filho and Dr. Fabiane Nascimento for their helpful suggestions during this study pre-design.</p>
      <p>The authors are indebted to Prof. Marcia Olandoski for statistical help.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by UNIPAR.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the doctoral thesis submitted by Jefferson J. Amaral dos Santos, from Pont&#237;fica Universidade Cat&#243;lica do Paran&#225;.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
